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the "spasm reactor" in your practic

The Machine Age man still possesses a Stone Age stomach; sometimes the job of merely coping with today's
environmental stress may prove too much. For some
(the "spasm reactors" in your practice), tension, anxiety and worry may find expression through the voice of
gastrointestinal or other smooth muscle spasm. To treat
these patients with antispasmodics alone is often to
miss the point of origin .of their disturbance; to rely
solely on tranquilizers often proves discouragingly slow
or ineffective in relieving spasm and pain.

To quiet and quell

Donnatal can promptly and effectively quell the spasm and quiet the tensions that trigger
it. Prescribed by more physicians thari any other antispasmodic-sedative, Donnatal continues to provide the
classic answer.

The "Donnatal Effect" The characteristic, over-all
effect of Donnatal has been observed in many thousands
of children and adults, clearly establishing its value as
a versatile sedative-antispasmodic. Outstanding in effectiveness, safety, economy, uniformity of composition
and dosage convenience, Donnatal continues to be desired and prescribed by a majority of physicians.

when the
'~ut issues"
get to him
he deserves

In a multiplicity of indications Particularly useful
when anxiety and tension accompany, aggravate or account for smooth muscle spasm, Donnatal is indicated
for the symptomatic relief of recurring, persistent or
chronic visceral spasm. More than two dozen distinct
and separate indications for Donnatal are listed on page
869 in the current PDR.
Brief summary Blurring of vision, dry mouth, difficult urination, and flushing or dryness of the skin may
occur on higher dosage levels, rarely on usual dosage.
Administer with caution to patients with incipient glaucoma or urinary bladder neck obstruction. Contraindicated in acute glaucoma, advanced renal or hepatic
disease or a hypersensitivity to any of the ingredients.
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each tablet, capsule or
each
5cc. of elixir (23% alcohol)
Extentab®
hyoscyamine sulfate ................ 0.1037 mg.
0.3111 mg.
atropine sulfate ........................ 0.0194 mg.
0.0582 mg.
hyoscine hydrobromide ............ 0.0065 mg.
0.0195 mg.
phenobarbital .................... ( '>' gr.) 16.2 mg.
(%gr.) 48.6 mg.
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QUIETS THE STRESS IQUELLS THE SPASM
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Epidemiology of Adverse Drug Reactions
LEIGHTON E. CLUFF

Department of Medicine, University of Florida
School of Medicine, Gainesville

There is a similarity in the approach taken by Dr. Wolf (Dr.
Stewart G .,- the 1967 Stoneburner
Lecturer) and Col. Moser to the
one I will present to you. Dr. Wolf
is interested in why some people
die suddenly and why others do
not. What are the factors responsible for predisposition? The major
theme of our studies on the epidemiology of adverse drug reactions has been to gain understanding of why some people will have
trouble and others will not when
given the same drugs in essentially
the same way and for the same reasons. Col. Moser spoke to the
problem of adverse drug reactions,
i.e., their recognition, identification, and documentation. Epidemiological methods allow us to identify reactions, when they occur,
and to establish the risk involved
in administration of drugs to patients.
In any epidemiological study
there are two pieces of information
that must be accumulated. One is
denominator data and the other is
numerator data. When we began
our studies about five years ago,
our initial attention was directed
toward assembling denominator
data. How many drugs are used?
What patients receive them? Under
what circumstances? These data
identified the population at risk.
One should also know the dosage
form in which the drug is administered, and have information on
the duration of therapy. Unfortunately, the latter two pieces of
72

information are difficult to obtain,
because, as Col. Moser has pointed
out, the accumulation of masses of
information on patients at risk and
the drugs they receive is an overwhelming task requiring automatic
data processing. At present, in
most hospitals, it is impossible to
retrieve information on dosage
form or duration of therapy, although in most instances it is possible to identify the population at
risk receiving given groups of
drugs.
Drug Usage in Hospitals
I will summarize some of the
pertinent observations that we have
made during the course of our investigations.
The most frequently used drugs
in a hospital, as you might expect,
are tranquilizers and sedatives. It
is interesting, however, in reference to Col. Moser's paying particular attention to tetracycline, that
in one survey at the Johns Hopkins
Hospital, five of the ten most commonly prescribed drugs were antimicrobial agents.
The studies that I will speak
about were confined largely to an
evaluation of drug usage and adverse reactions to drugs on a medical service at the Johns Hopkins
Hospital. This included an evaluation of private and public patients.
The results were in essence identical, so there is no point in differentiating them.
On the medical service at the
Johns Hopkins Hospital the aver-

age number of drugs given to a
patient during hospitalization was
11. This ranged from zero to 42
different drugs. We have identified
only one patient who received no
medication during hospitalization.
It is interesting to evaluate the
kinds of drugs patients receive. In
one study, evaluating all the patients in the hospital receiving
methicillin, we identified a patient
who received 37 different drugs,
and this patient received five different antimicrobial agents during
the course of hospitalization. In
other university medical centers,
the average number of drugs administered to patients on medical
services is about 10 to 14 different
medications during hospitalization.
Examining drug usage can be a
useful exercise. It's not just a collection of meaningless data. I
would like to point out one example of how this was important at
Johns Hopkins Hospital.
During the initial phase of our
study on drug usage, we became
aware that the surgical service used
the most chloramphenicol in the
hospital. We investigated the patients on the surgical service who
received chloramphenicol. Most of
the patients received the drug prophylactically, in an attempt to prevent wound infections. But the interesting thing was to determine
why chloramphenicol was being
used as a prophylactic drug, when
this is not considered advisable.
Two years before, one of the surgeons on the staff had done a study
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of the effectiveness of chloramphenicol in prevention of postoperative wound infections. He had
instituted a study with a doubleblind placebo and the housestaff
administered the drugs in random
fashion to the patients on the service, some getting chloramphenicol
and some getting placebo. The
study was conducted for six
months. The surgeon evaluated his
data, found no difference in the
frequency of wound infections, and
terminated his study. By this time,
the surgical staff had become accustomed to using chloramphenicol
prophylactically, however, and the
practice was perpetuated. When
this was brought to the attention
of the surgeon-in-chief, some curtailment in the use of chloramphenicol was possible.
Detection of Adverse Drug
Reactions
Identification of adverse drug reactions, when patients receive 11
different drugs, is a problem. When
a reaction occurs or when some
anticipated illness develops how
can the physician 1) be certain
that it is an adverse reaction to
a drug, and 2) identify the specific
drug responsible for the adverse
effect. When a patient develops a
febrile reaction or granulocytopenia
during hospitalization, and he is
receiving 42 different drugs, you
tell me which one is involved! We
can go to the literature and identify
those drugs incriminated previously,
but we may overlook the one that
is specifically involved.
Methods of Detection
What are some of the methods
that can be employed for detection
of adverse reactions? The AMA
Registry on Drugs and the Food
and Drug Administration are using
voluntary reporting, the system we
initially adopted. In epidemiological studies, however, one needs
a complete numerator and denominator. Otherwise incidence and
rates cannot be accurately deter-

mined. We instituted a voluntary
reporting system throughout the
Johns Hopkms Hospital for one
year. The average number of adverse reactions reported initially
was 15 per month. It gradually
went up to 25 per month at the
end of the year. We thought this
was under-reporting, so an effort
was made to examine the records
of patients upon whom reports had
been obtained, as well as those on
whom reports had not been obtained. Only one-tenth of all significant adverse reactions had been
reported voluntarily. Obviously voluntary reporting is incomplete. Us
greatest usefulness is in the identification of previously unrecognized
ill effects of a drug.
The only way to collect complete data is by personalized surveillance. This can be done, prospectively or retrospectively, and we
have done both. A retrospective
analysis is notoriously inadequate.
To evaluate this we selected the
records of patients who had been
given Warfarin. The ill effects of
anticoagulant drugs are readily
identifiable. In a retrospective
analysis 10% of the patients who
received this anticoagulant drug
had some manifestation of bleeding, gross or microscopic. The
commonest site of bleeding, of
course, was in the urine. Most
commonly the bleeding was microscopic. Occasionally, blood was
found in the feces, but subarachnoid hemorrhage and massive
bleeding into the pleural space following thoracentesis was demonstrable. This method too, however,
was an inadequate way of obtaining data, because doctors are not
good at recording reactions in patients' charts. This is illustrated by
the fact that the majority of the
patients rece1vmg Wafarin had
one urinalysis and had one stool
examination for occult blood done
during hospitalization and that was
the day of admission. Generally
these examinations were not repeated. The necessary tests were
not done to detect the most com-

mon sites of bleeding in patients
receiving anticoagulants.
Personalized prospective surveillance was the only way to obtain
complete information. Three
methods have been evaluated: 1)
surveillance of all patients receiving a particular drug in the hospital; 2) surveillance of all patients
with a particular disease in the
hospital, the drugs they receive,
and the reactions they may develop; 3) surveillance of groups of
patients, such as those on a medical service or surgical service. The
latter is the one that has proven,
in our hands, the most useful in uncovering information relevant to
the factors that predispose patients
to reactions.
Definition of a Reaction
Another problem is the definition of a reaction. It can be defined by mechanism involved, clinical features, or in terms of severity
or probability. Severity is relatively
easy to note: 1) fatal or lifethreatening; 2) requiring an antidote or long hospitalization; and 3)
an annoyance. The real difficulty
is documenting the probability of
a reaction. These are the systems
that we have employed : 1) A documented reaction is one known to
occur, with a clear temporal association with the administration
of the drug; on re-cha11enge the
patient has a recurrence of the reaction; or there is some confirmatory laboratory test establishing
that the drug is incriminated in
the patient's illness. 2) Probable
reactions that have a temporal relationship, are known to occur and
disappear on withdrawal of the
medication. We have ignored other
reactions which are possible, because we cannot in those instances
establish this as an adverse drug
effect.
I would like to show you examples of problems in identifying
drug reactions. A 6-year-old boy
with a tetralogy of Fallot was seen
in the hospital for surgical cor73
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rection of his cardiac defect. He
was put on penicillin and streptomycin prophylactically. Following
operation he developed progressively increasing fever, leukocytosis, mild anemia, weight loss, and
anorexia. He had multiple blood
cultures taken which were negative. He had no splenomegaly, nor
did he have microscopic hematuria or petechiae, but the surgeons
felt that he must have a postcardiotomy infection. The dosages
of the anti-microbial drugs were
increased, and others were added.
The therapy was continued for
seven weeks at which time I was
called in consultation. It was suggested that the patient might have
drug fever. Streptomycin, tetracycline, and erythromycin were
stopped without any termination in
the patient's course. Eight hours
after the penicillin was stopped, the
patient was afebrile and left the
hospital four days later. This boy
had fever as the only manifestation
of the ill effects of a drug, and
this was confused with infection.
A young woman was seen in the
emergency room because of a
streptococcal sore throat. She was
given penicillin. Within 48 hours,
she returned to the emergency
room with a florid confluent erythematous rash, and a diagnosis
of scarlet fever was made. The girl
did not have scarlet fever. Following recovery, after discontinuing
her treatment, she was given penicillin again and had a recurrence
of the reaction. Again identification of a reaction and differentiating it from a naturally occurring
disease complicated the identification of a drug reaction.
Adverse Reactions Occurring
in Hospitals

With this as background, let's
look at the overall problem of adverse drug reactions in the hospital.
On the medical service of the Johns
Hopkins Hospital 5% of all the
patients are admitted to the hospital with an adverse drug reaction.
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Four percent of the patients are
admitted to the medical service,
because of adverse effects of drugs.
Adverse drug reactions as a cause
of hospitalization represent the
seventh most common reason for
admission to the medical service.
Of those patients admitted to the
hospital who have a reaction at the
time of admission, 30% will have
a reaction to another drug during
the course of hospitalization. This
contrasts with an overall rate of reactions to drugs of 10% in all patients on the medical service. This
means that the patient who has
had a reaction to a medication has
a three-fold greater likelihood of
having a reaction to another drug
during the course of hospitalization. This identifies patients with
a pronounced predisposition to the
occurrence of reactions.
A patient with miliary tuberculosis who was comatose when admitted to the hospital, was put on
INH, P ASA, and streptomycin.
During the course of the first five
or six days of hospitalization she
defervesced, and regained consciousness. She developed an exfoliative rash and because of this
it was necessary to stop all of her
medication. At that time her temperature declined and her exfoliative rash disappeared. She still had
her miliary tuberculosis, so she
was put back on INH, but this
time she developed a folicular
rash over the face. An industrious
intern aspirated one of these and
grew a Staphylococcus albus. He
was alarmed that the patient might
be developing staphylococcal sepsis, and gave the patient an injection
of penicillin. She went into anaphylactic shock, requiring hydrocortisone and norepinephrine. All
drugs were again stopped, except
that steroid and digitalis were continued. Again, the patient required
treatment for her tuberculosis.
While on prednisone she was given
a single dose of P ASA and had a
frank chill with a prompt rise in
temperature. Subsequently, she was
given a single dose of streptomy-

cin, and again had a prompt chill
and recurrence of fever. During
the course of these 70 days of hospitalization, this patient had documented reactions, to paraminosalicylic acid, penicillin, streptomycin,
and INH.
I would like to return briefly to
the problem of severity. Not all
reactions to drugs seen in hospitals
are mild. Mild reactions account
for almost half of those observed.
Correspondingly almost half of the
patients had reactions sufficiently
severe to warrant the physician's
giving an antidote, prolong hospitalization or to threaten life.
Seven percent of the patients with
adverse reactions had life-threatening or fatal reactions.
Gastrointestinal rea.c tions to
drugs are particularly common in
women. In a report by Jordan and
Dingle, women with colds also
have an increased frequency of
nausea, vomiting, and diarrhea.
Whether this is a specific effect of
drug reactions or whether it is a
peculiarity of females, I don't
know. Nevertheless, in all of our
subsequent studies we have eliminated the minor gastrointestinal reactions, because we cannot be certain of the relationship to the drug
itself. It should be emphasized,
however, that adverse effects of
drugs frequently mimic natural disease.
Tranquilizers and sedatives rank
far above any other drugs as causes
of ill effects in patients. Antimicrobial and cardiac drugs, however,
are near in importance of ill effects
in hospitalized patients. There is
wide variation in rates of reactions
to different drugs. The range was
from 27% (probenecid) down to
3.1% (mercaptomerin). Col.
Moser made the point that before
the physician can significantly
weigh benefit with risk, he must
have such data as this, citing incidence as well as severity. Unfortunately, such data is usually lacking at the present time. In contrast
to Col. Moser, however, I do not
believe the present systems of the
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AMA Council on Drug and the
Food and Drug Administration will
get us to the point of determining
the exact risk.

Severity of Reactions
Patients do die of drug reactions
in the hospital. During one threemonth period on the medical service of the Johns Hopkins Hospital,
there were five deaths due to drugs
in hospitalized patients. It is possible for the physician to avoid
some of these lethal effects as il1ustrated by these patients. A middle-aged man admitted to the
hospital with chronic pulmonary
disease had a coin lesion in his lung.
During the course of his hospitalization it was decided that he should
be bronchoscoped. The pre-bronchoscopic medications were promazine, pentobarbital, and morphine. This medication was given
and he was taken to the endoscopy
room where he developed respiratory arrest. He was given artificial
respiration and returned to the
ward without bronchoscopy with
the advice of the endoscopist that
the patient should not be bronchoscoped because of the problem of
premedication. Two weeks later
there was a change of physicians
on the ward. They were fully aware
that the patient shouldn't be bronchoscoped, but they needed a study
to identify the nature of his pulmonary disease. A bronchogram
was decided upon. The pre-medications for bronchography were promazine, pentobarbital, and morphine, of which the physicians on
the ward were unaware. The premedication was given, and within
a very short time the man went into
shock, cardiac arrest, respiratory
depression, and died. Another patient was a young woman who during her prepartum period on the
obstetrical service had been found
to have a minor urinary tract infection and was given sulfisoxazole.
Her bacteriuria cleared, but she developed an urticaria! and erythematous rash. A note was written

in the progress notes by the obstetrician that the patient was allergic
to sulfonamides and the drug was
discontinued. Following delivery,
the woman was again found to
have bacteriuria. She was now no
longer an obstetrical patient and
was referred to the medical clinic
for evaluation. The obstetrical records were kept in a different part
of the chart from the medical records. Frequently the internist
doesn't read the obstetrician's
notes. Nevertheless, the internist
recognized the bacteriuria and represcribed sulfisoxazole. Very
shortly thereafter she had gross
hematuria. She was admitted to the
hospital hypertensive, had sulfonamide crystalluria, and died in renal
failure. Autopsy revealed she had
typical sulfonamide crystals in the
tubules of her kidney. She undoubtedly died of sulfonamide-induced allergic vasculitis. This illustrates some of the settings in
which lethal effects of drugs can be
observed and how they can be
avoided.
We have been unable to confirm
any relationship in the patient with
atopy and the subsequent development of allergic or other reactions
to drugs. However, history of an
adverse reaction to any drug is associated with a significant increase
in the frequency of reactions to
other drugs subsequently administered. So there is something peculiar about people who have trouble
with drugs. Whether this is heritable or what the factors are that
are particularly involved remains to
further study.
Number of Drugs Administered
An important factor related to
the occurrence of adverse reactions
to drugs in hospitalized patients is
the number of drugs administered.
When one exceeds a total of six
drugs there is a logarithmic increase in the likelihood of the patient's having an adverse reaction
to at least one drug. Of the patients receiving 16 drugs during

the period of hospitalization, 45%
of them will have an adverse reaction to at least one drug that they
have during the period of hospitalization. If I were to recommend
one thing that would significantly
reduce the problem of the ill effects
of drugs, it would be to curtail the
use of innumerable drugs. This is
undoubtedly the most important
factor we have thus far identified.
Why this curve is logarithmic I
don't know. Our present feelings
are that much of this is a problem
of drug interaction, interactions
that conceivably have not been
identified and are unrecognized.
As you would expect, of course,
there is a relationship between the
number of drugs administered and
the mortality rate and period of
hospitalization, indicating that people who get lots of drugs are generally the sickest.
In studies of pneumonia the rate
of allergic reaction to penicillin
rarely is less than 10% . Yet in patients receiving penicillin in V.D.
clinics, the rate is usually less than
1 % . Is there a relationship between
the presence of infection and the
occurrence of allergic reactions to
drugs? We have shown such a relationship which I think deserves
further study. It's our present supposition that a severe infection may
serve as an adjuvant to an immunological response to a simple
chemical agent.
Over three times more men than
women receiving penicillin in the
hospital will have allergic reactions
to this drug. By history the men in
this study had received penicillin in
the past no more frequently than
women .

Conclusion
I would like to conclude by citing two other rather interesting observations we have made. Threequarters of all the patients in all
our surveillance who have allergic
reactions to drugs have had peptic
ulcer, ulcerative colitis, or neo75
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plastic disease of the gastrointestinal tract. Of these patients, threequarters of the drugs producing
allergic reactions are administered
orally. The rates of allergic reactions to individual drugs in patients
with gastrointestinal disease as opposed to those without gastrointestinal disease receiving the same
medication, are significantly increased. What the impact is of inflammatory gastr,ointestinal disease
1) upon the absorption of the drug,
2) upon its metabolism, and 3)
upon its antigenicity has not been
investigated before. But from these
studies it is suggested that inflammatory disease of the gastrointestinal tract may be an important factor predisposing patients receiving
oral drugs to occurrence of allergic
reactions. It has commonly been
supposed that patients with autoimmunological disorders, e.g., systemic lupus erythematosus, may
have a predisposition to multiple
allergic reactions to drugs. In our
evaluation of this problem, there
is no significant increase in the occurrence of allergic reactions to
drugs in these patients.
I would like to end with some
unresolved questions. We obviously
need more information on rates of
reactions to drugs. Without this the
physician is ill prepared in estimating risk as opposed to benefit. As
Col. Moser pointed out, we can go
20 years before identification of a
possible relationship of thrombocytopenia to tetracycline. It took
six years to identify aplastic anemia
in relation to chloramphenicol.
There must be some better way to
identify the ill effects of drugs than
just by the casual, incidental, periodic reporting in the literature by
physicians who suspect or identify
relationships. I happen to think
this is the greatest value of the
Food and Drug Administration
and the AMA Council on Drugs
Registry on adverse reactions. Unfortunately, however, most of the
reactions reported are those that
we know exist. As far as I am
aware, in the FDA program in op76

eration in a multiplicity of hospitals voluntarily reporting adverse
effects of drugs has not identified a
single previously unrecognized ill
effect of a drug that would not have
been detected as promptly otherwise. We need a great deal more
information about how drugs are
used outside of the hospital by patients who can buy them in the
drug store without prescription. I
was recently amazed when a pharmaceutical representative came into
my office, and I commented about
how many drugs patients kept in
their cabinets at home. The pharmaceutical representative was intrigued and came back the following day having counted the number
of drugs in his cabinet-90! It is
my impression that most of the
patients who developed Fanconi
syndrome from outdated tetracycline were children whose mothers
had been given tetracycline by the
physician, had kept it on the shelf,
and then when the child got ill had
given it to him. I think it's critically
important that the public be informed as much about the problem
of drugs as the medical profession.

We do it poorly. We let journalists
write about how horrible hospitals
are, but I have yet to see anybody
in the medical profession make
any exertion to inform the public
about the use of non-prescription
drugs. We need a great deal more
information about what heritable
factors cause reactions to drugs.
I have indicated some factors
that suggest this may be far
more important than we have previously recognized. We need more
information on other factors-diseases and organ function-which
influence predisposition to drug reactions. Most studies done on the
metabolism, absorption, and excretion of drugs are performed in
normal people. They are not comparable to patients in the hospital
who have fever, renal failure, minor
abnormalities of liver function, who
have respiratory embarrassment
and are in heart failure. We need
a great deal more information
about the reactions to drugs in patients who are sick, as well as we
need increasing information about
the problems of drugs in people
who are well. Thank you.

Pharmacology of Anti-Anginal Agents
MAURICE McGREGOR

Department of Medicine, McGill University Faculty of Medicine,
Montreal, Canada

For me, 1967 is a double centennial year; it commemorates both
the year of Canadian Federation
and the first use of nitrites for
angina pectoris. It was in 1867
that Lauder Brunton published his
paper in the Lancet on the use of
"Nitrite of Amyl for Angina Pectoris" (Brunton, 1867). It is sad
to reflect that apart from this one
lucky break this is really the only
significant progress we have made
in the medical treatment of angina
pectoris in the last hundred years.
The reason for this lack of progress
is that we did not understand why
nitrites were so beneficial and, consequently, we supplied explanations
which were incorrect. Having done
that, we subsequently have tried
to produce better drugs with the
same presumed action. When Brunton wrote his paper he deduced
that the pain of angina was related
to an elevation of blood pressure.
He knew that nitrite of amyl could
produce prostration and a thin
thready pulse, and he thought it
probably worked by lowering the
blood pressure. For some time
thereafter other drugs that were
supposed to lower blood pressure
were given therapeutic trial. Then,
it was discovered that injection of
nitrites into the coronary artery of
an animal caused an increase in
coronary flow. From this time on
it was assumed that nitrites relieved angina pectoris by increasing coronary flow. It is for this
reason that, if you want to look up
anti-anginal drugs in any contemporary textbook, you must look
them up under the title of "Coronary Vasodilator Drugs."
MCV QUARTERLY 3(2): 77·79, 19&7

For the last 40 years or so manufacturers have continued to produce more potent vasodilator drugs
as judged by their ability to increase coronary flow in the normal
heart. Unfortunately none of them
has worked. The drug that drew
my attention to this dilemma is
one of the most potent of these
preparations, dipyridamole (Persantin). While nitroglycerin produces only a small increase in
coronary flow, lasting from 30 seconds to 1 minute, dipyridamole,
given in a reasonable dose intravenously or by mouth, may double
coronary flow for 20 to 30 minutes. It will do this without
increasing myocardial oxygen consumption, so that the whole myocardium and the coronary sinus
blood oxygen content increase proportionately. This ought to be
beneficial if increasing coronary
flow is going to relieve angina, and
for this reason we carried out a
careful clinical trial of this agent
(Kinsella, Troup, and McGregor,
1962). We could find no therapeutic effect at all. Following this
experience we decided to pause
and try to review the patho-physiology of angina and to consider in
what ways it might theoretically be
influenced by therapy.
Pathologic Physiology of
Angina Pectoris
Firstly, we now know that angina pectoris is not just a sensation
of pain and discomfort. It is a
syndrome which includes not only
pain, but also electrocardiographic
changes, a shift to anaerobic me77
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tabolism with production of lactate
and acute left ventricular failure,
when the involved muscle mass is
large enough. We also know that
this syndrome occurs whenever
there is a discrepancy between the
demand for myocardial oxygen
and its supply. This discrepancy
may, therefore, be correctable by
reducing oxygen consumption or
by increasing oxygen supply.
Normal oxygen supply demands
fully oxygenated blood and normal
hemoglobin. When the angina! patient suddenly gets worse it must
not necessarily be concluded that
one of his coronary arteries has
become occluded, though this may
of course be occurring. It could
well be that his hemoglobin has
dropped due, e.g., to bleeding piles
or a peptic ulcer. Alternatively he
may have become anoxemic due
to pulmonary embolism or pneumonia; or he may have inactivated
up to 20% of his hemoglobin by
smoking excessively. Likewise, his
coronary flow may be very dependent on an adequate arterial
pressure. Thus angina may be precipitated in the hypertensive patient with coronary disease by the
successful treatment of hypertension. Whenever angina becomes exacerbated, these possibilities should
be considered first.
The discrepancy between oxygen
supply and demand can also be
influenced, of course, by changes
in myocardial oxygen consumption. Dr. Richardson (Dr. David
W., an earlier speaker at the
symposium) has been telling us
that the amount of tension developed by the muscle fiber and
the rate with which it is developed
are the two critical determinants
of oxygen consumption. However, the tension developed is influenced by two major variables.
One is the amount of pressure developed in the ventricular chamber,
and the other is the ventricular
volu.me. According to the relationship between tension, pressure,
and radius described by Laplace,
the tension necessary for each fiber
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to develop a certain pressure will
increase with the radius of curvature of the ventricle. A small ventricle can thus produce the same
pressure with a smaller wall tension. It is more efficient. All other
things being equal then, one might
expect angina to be exacerbated
by ventricular enlargement and improved by reduction in ventricular
size. Fear or emotion causing increased sympatho-adrenal activity
will increase both the force of
contraction, the rate of development of tension, and the heart rate.
These are good reasons why the
blocking agent Propranolol, referred to earlier in this symposium,
ought to raise the angina! threshold. The disappointing thing is
how relatively poorly is does work,
and I think, used at random in an
angina! population, this drug is
probably going to have more dangers than benefits. There are
people, however, such as the thyrotoxic and the patient who gets
pain associated with emotion, in
whom I suspect this drug will
prove to be extremely beneficial.

Mechanism of Action of Nitrites
Let us now consider the possible
mechanism of action of the nitrite
drugs, because these are the only
really useful group of drugs available to us. First of all, it is clear
that they do not just act by relieving pain. They are capable of
lowering ventricular end-diastolic
pressure, of abolishing the lactate
production in the myocardium, and
of abolishing the electrocardiographic changes of angina. The
question is how they achieve this
effect. Theoretically, they might
either decrease myocardial oxygen
consumption, or increase oxygen
supply, or do both at once.
The prime effect of the nitrites is
on vascular smooth muscle, and
they cause an increase in large
vessel diameter with veno-dilatation. When administered to a resting subject or to an anesthetized
animal there is a fall in venous

pressure, venous return to the
heart, ventricular volume, cardiac
output, and blood pressure. As we
have seen, these effects should reduce myocardial oxygen consumption and may well explain the relief obtained by this drug in the
resting subject. However, nitroglycerin will also produce relief in the
exercising subject, and it is unlikely that the same mechanisms
operate. For example, we have
found that when patients are cycling on an ergometer a nitroglycerin tablet may actually increase
the cardiac output, and the hypotensive effect of the drug is almost
completely abolished (Hoeschen et
al., 1966). Thus we have turned
again to the possibility that nitrites
may indeed exert their effect by
changing coronary flow.
Now I would like to distinguish
carefully between increasing coronary flow in a normal heart and
re-distributing flow to the most
ischemic areas of a chronically
diseased heart. On consideration it
would seem that the very last drug
that you would choose to relieve
angina pectoris is one which increases coronary flow in the normal
heart. There is already present an
extraordinarily effective mechanism
which will increase or reduce coronary flow according to the local
metabolic need, and as far as we
can see it is geared very closely
to oxygen tension. Any substance
which increases coronary flow in
the normal heart must do so by
interfering with this autoregulatory
mechanism, and it has been shown
that this mechanism is completely
paralyzed following a dose of a
potent vasodilator drug such as
dipyridamole (Fam and McGregor,
1967). This cannot be beneficial if
local hypoxia is already causing
maximum flow to the most ischemic areas of heart muscle. Indeed,
in the presence of coronary narrowing it might even have an adverse effect by increasing flow to
non-ischemic areas of heart muscle.
In atherosclerotic coronary disease it is the large coronary vessels
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which are narrowed. Studies which
Dr. W. Fam and I are carrying out
at present indicate that these vessels take no part in autoregulation.
Thus to increase flow through
them it is necessary to use a vasod ilator substance which will act at
this site in the coronary tree. It
may well be that the diseased vessels themselves are incapable of
vasodilatation, but as you well know
the ischemic areas of muscle may
be partly or wholly supplied by
collateral vessels ansmg from
healthy neighbouring coronary arteries. A drug which acts on these
arteries may be expected to increase flow into the ischemic areas
of the heart through collateral
channels. It is probably significant
that this is precisely the site of
action of nitroglycerin.
Angiographic observation tells us
that a nitroglycerin tablet will increase the size of all the larger
coronary arteries for several minutes, and we have found that the
effect of nitroglycerin is almost
completely confined to the larger
vessels (McGregor a nd Fam,
1966). Furthermore, when a coronary branch of a dog is gradually
narrowed, thus creating obstruction, nitroglycerin can be shown to
augment the collateral flow into the
ischemic area. Dipyridamole, which
acts principally on the small coronary vessels does not have this
effect (Fam and McGregor, 1964).
Conclusion
In conclusion I would like to
stress that these observations do
not constitute direct evidence of
the mechanism whereby the nitrites
relieve angina pectoris. It is probable that they are capable of causing some reduction of myocardial
oxygen consumption. However,
there is increasing indirect evidence which suggests that the site
of action of these drugs is principally on the large coronary arteries. Their administration may thus
relieve coronary spasm, if this ever
causes angina, and more impor-

tantly will increase collateral flow
into ischemic areas of myocardium
when collateral channels have become enlarged. Drugs such as dipyridamole which seem to act on
the small vessels, which are the site
of autoregulation, are unlikely to
have this effect. Indeed, if the autoregulatory mechanism is necessary to direct a limited blood flow
to the most ischemic areas of myocardium, such drugs may theoretically be harmful.
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Some Perspectives on lmmunosuppressive
Drugs
ROBERT S. SCHWARTZ

Department of Medicine, Tufts University School of Medicine
Boston, Massachusetts

My coming here to Richmond
to discuss immunosuppressive
drugs is surely carrying coals to
Newcastle, because the Medical
College of Virginia has been a
leader in this field, particularly with
reference to transplantation of the
kidney. I don't know what I can
tell you that you already don't know
about immunosuppression; nevertheless, you might be interested in
learning of our own experience
with these drugs.
The four main classes of cytotoxic drugs of interest to the immunologist are the alkylating agents
such as nitrogen mustard and cyclophosphamide, purine antagonists
( 6-mercaptopurine and azathioprine), the pyrimidine antagonists
such as 5-fluorouracil, and finally
the extremely interesting and potentially versatile agent methotrexate, a folic acid analog. Our laboratory has chosen to focus its
attention on a single class of these
compounds, the purine antagonists,
in an attempt to find out as much
about their immunological properties as we can. I plan to discuss two
aspects of this work: 1) Some of
the effects of 6-mercaptopurine (6MP) in experimental animals, and
2) some of the effects of its analogue, azathioprine, in man.

Purine Antagonists
6-Mercaptopurine, a rather simple analogue of hypoxanthine, has
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very powerful effects on cellular
metabolism. Azathioprine was synthesized with the hope that it would
have a higher therapeutic index
than the parent compound. Its imidazol ring was attached to the sulfur atom in the expectation that
this would slow down the metabolic
degradation of 6-MP. Azathioprine
does in fact appear to have a higher
therapeutic index when compared
to 6-MP in mice, but this has not
yet been established in man.
6-Mercaptopurine has two major
immunological properties that can
be demonstrated in experimental
animals. The first of these is suppression of humoral antibody synthesis. Animals given only a oneweek course of 6-MP fail to
elaborate a normal primary immune response. The second major
effect of this material is on transplantation immunity; a significant
prolongation of homograft survival
can be obtained in a variety of animals treated with 6-MP.
One of the fundamental problems in this field , in fact the problem which I believe to be central
to rational and successful immunosuppressive drug therapy, is that
despite the very specific biochemical sites of action of various antimetabolites, the final result in an
organized cell is its death. Regardless how specific the biochemical
effect of an antimetabolite may be,
the end result is disintegration of
the metabolic cycles of the cell.
Therefore, the central question is

whether any specific immunological effects can be obtained by the
use of materials which are really
cell poisons. In my view, it is
worthless to pursue a generalized
destruction of the immune capability of an individual in order to achieve immunosuppression,
whether in the treatment of an immunological disease or in the establishment of a functioning tissue
graft. We would be trading a possible clinical effect for an immunological cripple.
Immunological Effects of
Cytotoxic Drugs
Quite surprisingly, specific immunological effects can in fact be
obtained by cytotoxic drugs. Depending upon the experimental design, it is possible to delete a
specific immunological reactivity
without affecting an immune response to a randomly selected antigen. Such an animal is not an
immunological cripple. It has acquired immunological tolerance of
an antigen used during the period
of chemotherapy. If this can be
obtained in an experimental animal, there is every reason to believe that it can be also achieved
in man.
One other effect of 6-mercaptopurine, and probably of other
agehts, which · is of considerable
importance in attempting to assess
the reason for their clinical effectiveness, is iJJustrated by experiMCV QUARTERLY 3(2): 80-81 , 1967
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ments on suppression of the Arthus
reaction in hyperimmunized rabbits. In these animals the peripheral
expression of immune injury has
been eliminated without an effect
on the synthesis of antibody. Or,
to put it differently, 6-MP has, in
addition to its capacity to suppress
antibody synthesis, a very potent
anti-inflammatory effect. This will
be seen time and again in clinical
material.
Mechanism of Action of
Cytotoxic Drugs
The mechanism of action of
these drugs in patients with diseases presumed to be on an immunological basis is far from clear.
Some of the questions we have
posed include: 1) Does immunosuppression in fact occur in patients treated with these agents?
2) Can selective immunosuppression be achieved in man? 3) Is
there any correlation between the
degree of immunosuppression
achieved with these agents and the
clinical response? In order to gain
some insight into these questions,
the immune responses of a group
of patients treated with either azathioprine or amethopterin were
measured . Keyhole limpet hemocyanin (KLH), a powerful antigen
long used in experimental animals,
but never before applied to the
study of human immunity, was
used to evaluate the primary response. In normal subjects it provokes both a circulating antibody
response and classical delayed hypersensitivity. Diphtheria toxoid
was used to study the secondary
response. In about a third of the
patients, both primary and secondary immune responses were
completely ablated during chemotherapy. In another third of the
patients the primary immune response was completely suppressed,
but a relatively normal secondary
immune response occurred. Another third of the patients had a
most interesting type of immune
response while on continuous or

even intermittent drug therapy.
This can be called the "accordion"
effect. When compared to the normal immune response, the induction period is greatly prolonged.
However, once antibody synthesis
occurs, there is a very rapid burst
of antibody formation. This occurs
even while the patient is on continuous immunosuppressive drug
treatment.
One of the interesting observations that came out of this study
was the effect of these drugs on
two classes of immunoglobulins,
IgM and JgG. In two-thirds of the
patients on immunosuppressive
drug therapy a greatly prolonged,
but quantitatively normal IgM response occurred in the absence of
any detectable lgG antibody synthesis. Thus, an apparently selective suppression of one molecular
class of antibody may be obtained
with both azathioprine and methotrexate in man.

Clinical Results
The question whether continuous
immunosuppression is required to
maintain a clinical remission in patients with immunological diseases
probably has a negative answer in
light of the "accordion" effect mentioned previously. This is another
reason for believing that treatment
with the currently available immunosuppressive drugs need be
pushed to the point of destruction
of all immune capabilities of the
patient.
The third question, is there any
correlation between the degree of
immunosuppression and the actual
clinical result, is extremely difficult
to answer. In many patients there
is no such correlation. Extensive
depression of immunity does not
indicate that a patient will respond
clinically. Furthermore, some patients with a minimum or no immunosuppression h ave dramatic improvements. We believe that many
of the effects of antimetabolites
we have seen in man. may be
due to their important, but poorly

understood, anti-inflammatory actions.
Conclusion
In conclusion, the antimetabolites have proven extremely interesting in the laboratory for the
exploration of the mechanism of
antibody synthesis and related
problems. They have also proven
to be extremely useful and interesting materials in the clinic.
Whether they are going to replace
any other standard forms of therapy, such as the corticosteroids, is,
in my view, doubtful. Their use at
the moment is experimental and
their ultimate place in clinical medicine is by no means settled. They
appear to have two important
effects in man: 1) Suppression of
antibody formation which can be,
in many individuals, selective; and
2) Very important anti-inflammatory properties which may account
for their effects on immune injury
and for some of the very rapid responses seen in individuals treated
with these agents.
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The Pharmacology of Newer Diuretics
ALBERT J. WASSERMAN

Department of Medicine, Medical College of Virginia, Richmond

Diuretics continue to be among
the commonest of all prescribed
items. Until recently, the physician
needed to have little concern about
the dose of the agent he was choosing because firstly, the dose-response curve tended to be startlingly flat, and secondly, there was
little chance of inducing an excessive diuresis, regardless of dose.
Now that furosemide (Lasix) and
ethacrynic acid (Edecrin) have become available, we find that one
must indeed titrate the dose to the
particular patient, and must appreciate for the first time the complications which can result from an
excessive diuresis. Finally, with the
availability of triamterene and MK870 ( Colectril, not yet available),
one must appreciate the importance of the distal tubular mechanism for potassium for sodium exchange. The additive effect of these
exchange inhibitors can be of considerable clinical usefulness .
Adverse Effects of Diuretics

Figure 1 illustrates the excessive
diuresis which can result from the
newer, more potent diuretics. This
R_atient was hospitalized and started
on what seemed like a reasonable
dose of ethacrynic acid, but she
lost 35 pounds in four days. Fortunately, this patient had no adverse effects, but this is the very
circumstance in which the series
of adverse effects shown in table 1
can occur. The most important of
these is hypovolemia. This is particularly likely to occur in the patient with cirrhosis or nephrosis.
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The problem is one of developing
circulatory collapse, shock. The
only treatment advisable then is
the infusion of salt-poor albumin.
Such episodes have been reported
with some real frequency. The
problem of inducing excessive potassium loss is primarily related to
the patient who is also taking digi talis and who becomes much
more susceptible to the ectopic activity of the cardiac glycosides. Hypochloremia will induce diuretic
refractoriness to mercurials, but
not to these new agents. In spite of
electrolyte derrangements and in
spite of reduction in renal blood
flow, furosemide and ethacrynic
acid will continue to exert diuretic
effects. Hyponatremia may develop,
particularly in the patient who is
having a marked saluresis and who
replaces the volume with tap water.
The cause of muscle cramps, the
weakness, the "washed-out" feeling, is still not clear, but the symptoms are well-recognized in patients in whom a marked prompt
diuresis ensues. The relationship to
thrombosis and the development of
gout are not clear, but there is
some circumstantial evidence suggesting that these can occur during
diuresis. In summary, one must
avoid having too rapid and too
massive a diuresis.
Table 2 suggests some measures
to avoid adverse effects of diuretics.
The most important is the first:
choose a sub-maximally effective
dose. This requires knowing something about the dose response to
these new agents. The only way to
judge the response, of course, is to
MCV QUARTERLY 3(2): 82-90, 1967
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TABLE 1
Results of Excessive Diuresis
1. Hypovolemia
a. Reduction in renal blood
flow
b. Circulatory collapse
2. Hypokalemia
a. Digitalis intoxication
3. Hypochloremia
a. Mercurial refractoriness
4. Hyponatremia
a. Water intoxication
5. Muscle cramps
6. Weakness
7. ? Thromboses
8. Acute gout
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TABLE 2
Routine Measures on Initiating a
Diuresis
1. Choose a submaximal diuretic
dose.
2. Record weights and fluid balance.
3. Restrict activity.
4. Reduce sodium intake.
5. Restrict fluids to 1 to 1.5 liters,
especially the day after diuresis.
6. Watch blood Na, K, Cl, HCOs,
urea and hematocrit.
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Fig. 1- An excessively rapid response to ethacrynic acid.

record weights and fluid balance.
Weights must be recorded by every
out-patient who is taking diuretics
for their diuretic properties. If a
poor response from the diuretic
occurs, restnctmg the patient's
physical activity during the day
will often enhance the diuresis,
since in heart failure, physical activity reduces renal blood fl.ow.
Fluids need be restricted only if
the patient appears to be one who
has the habit of ingesting water
followin g a marked diuresis. No
simple rule can be offered for the
frequency of determining serum
electrolytes. If the patient is having
a marked response, they should be
checked. Obviously, if he is hav-

ing a poor response, they should
be checked. With the new agents
which continue to be effective even
in the face of electrolyte abnormalities, it is necessary to check them
with some regularity, like once every week or two.

vantage with the exception of a
more prolonged activity. In this
sense it more closely resembles
chlorthalidone. It has no other advantages and no other disadvantages.
Furosemide

Quinethazone

The first new agent to consider
is quinethazone (Hydromox). Figure 2 shows the structural formula
for quinthazone. Note the similarity to chlorthalidone (Hydroton)
and to chlorothiazide (Diuril).
Quinethazone is thus another one
of the large group of thiazide derivatives. It has no particular ad-

The structural formula for furosemide (Lasix) is shown in figure 3.
Furosemide has also been called
fursemide and frusemide. This is
an agent whose activity-structure
relationship is still not clear. Some
would suggest that it is the common grouping with the thiazides;
others would suggest that it is the
free carboxyl group which is re83
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Fig. 2-Structural formulae of quinethazone (I;:lydromox), chlorthalidone
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NH-CH,

H,N02S

0

COOH

Fig. 3-Furosemide (Lasix), 4-chloro-N-(2-furylmethyl)-5-sulfamoyl-anthranilic
acid.

sponsible for its diuretic activity.
It is clear that it is different from
the thiazides in several ways.
Firstly, it is active in an animal in
which there is no liver. The thiazides require the presence of the
liver before diuresis will ensue.
Secondly, furosemide causes a decrease in bicarbonate excretion in
contrast to the typical thiazides.
Thirdly, there is a markedly different order of efficacy. Furosemide clearly works in the ascending loop of Henle. It probably
works in the proximal tubule, although animal micropuncture studies give contrary evidence. It has
been said, though, and we have all
been taught, that some 80% of the
normal glomerular filtration is reabsorbed in the proximal tubule.
If a diuretic were 100% effective,
theoretically it could only increase
urine output to 20 % of the filtration rate if it had no activity in the
proximal tubule. Furosemide can
produce a diuresis of as much as
one-half of the glomerular filtration rate, and this has been used as
evidence that it must alter the
proximal tubular reabsorption of
salt and water.
Figure 4 shows the human response to furosemide contrasted
with hydrochlorothiazide at 50 to
75 mg of each. Note that furosemide produces a larger diuresis,
natriuresis and chloruresis, but importantly, no greater kaluresis. For
each milliequivalent of sodium excreted, furosemide causes less potassium excretion than do the thiazides.
Furosemide is very rapidly effective, acting in minutes when
given intravenously. Its maximum
effect occurs within two hours when
given orally. The duration of effect
is correspondingly short. The dose
response curve is shown in figure
5. In the case of hydrochlorothiazide, increasing the dose from 50
to 100 mg causes only a modestly
increased natriuresis, whereas increasing the dose of furosemide
from 50 to 100 mg causes a very
considerable difference. Furose-
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mide, therefore, differs in potency,
that is, more diuresis per milligram,
but more importantly, it differs in
efficacy, giving a maximum response beyond what can be achieved with any of the thiazides.
The toxicity of furosemide is
still under investigation. Table 3
lists the toxic reactions. Rare hypersensitivities, usually rashes and
rare, not definitely causally-related
alteration in blood counts have
been reported. N ausea and vomiting appear to be clearly dose-related and will occur quite frequently at single doses exceeding
200 mg. Furosemide causes hyperuricemia regularly and will precipitate acute gout occasionally. Pancreatitis and hyperglycemia have
now been reported in association
with furosemide therapy, but are
not yet established clearly as causally related. The extent of the
hyperglycemia appears to be considerably less than .that which occurs with the benzothiadiazines.
The major problem with furosemide is excessive diuretic effect.
This is the major adverse effect in
the use of this agent.
In summary, then, furosemide is
some three to five times as efficacious as the thiazides and causes
less potassium loss. Because it is so
rapidly effective, it has been used
in the treatment of pulmonary
edema and in cerebral edema. It is
important to note that it has a
steep dose response curve and that
it continues to be effective even in
the face of electrolyte derrangement, hypovolemia, and azotemia.
Ethacrynic Acid

The structural formula for ethacrynic acid (Edecrin) is shown in
figure 6. Note here the absence of
the sulfamyl group, but again the
hallogenated cyclic structure. The
free carboxyl group is thought to
be a major determinant of its activity. This agent appears to work
on the identical tubular mechanisms affected by furosemide. If one
gives a maximally effective dose, of
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either furosemide or ethacrynic
acid, and then gives the other agent,
no further response ensues. This
would tend to indicate that the
same mechanisms are affected by
the two agents. Figure 7 shows the
pattern of electrolyte excretion; a
marked chloruresis, natriuresis, diuresis, and a minimal kaluresis.
This is similar to the pattern shown
for furosemide (fig. 4). When
ethacrynic acid is given intravenously, an extremely prompt and
massive response can be expected.
Ethacrynic acid is available for parenteral use and is recommended
in the treatment of pulmonary

a very steep dose response relationship. One patient whom we treated
in the metabolic ward is shown in
figure 9. Note that with gradually
increasing doses from 50 to 100
mg, there was essentially no response in weight. With an increase
to 150 mg, there ensued a slow but
steady diuresis until dry weight was
obtained. This was a patient known,
from our previous experience with
her, to have highly resistant congestive heart failure.
Table 4 indicates the toxicity,
which is probably identical to what
was listed for furosemide. Rare
rashes and thrombocytopenia have

edema. A diuresis of 500 or 600
ml in one hour is not unusual. This
is equivalent to using a phlebotomy
or venous tourniquets to reduce the
circulating blood volume. Figure 8
illustrates the response of one such
patient. One and one-half liters of
urine had been passed in one hour
after 50 mg of intravenous ethacrynic acid, and about 3 liters by
three hours.
The dose response curve is also
shown in figure 7. There is an increasing response until one reaches
a dose of 200 mg, and at that point
maximal therapeutic effect has
been achieved . So again, there is

Cl

TABLE 3

Cl

Toxic Effects of Furosemide
1. Rare hypersensitivity
2. Nausea, vomiting (dose related)
3. Hyperuricemia and gout
4. Pancreatitis
5. Hyperglycemia
6. Excessive effect
Hypovolemia; hypochloremic
alkalosis; hypokalemia; hyponatremia
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Fig. 6-Ethacrynic acid (Edecrin), 2, 3-dichloro-4-(2-methylenebutyryl) phe·
noxyacetic acid.
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TABLE 4
Toxic Effects of Ethacrynic Acid
1. Rare hypersensitivity

2. Nausea, vomiting, diarrhea
(dose related)
3. Hyperuricemia and gout
4. Tinnitus, vertigo, deafness
5. Excessive effect
Hypovolemia; hypochloremic
alkalosis; hypokalemia; hyponatremia
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been reported; nausea, vomiting,
and diarrhea appear to be doserelated. Hyperuricemia and gout
will occur. Tinnitus, vertigo, and
deafness have been reported with
ethacrynic acid. It would appear to
be a function of the acute change
of the dynamics across the inner
ear endolymph, since continued
therapy with the agent is not associated with continuing or worsening of these symptoms, but
rather they tend to disappear over
a few days as soon as fluid balance
appears to be more stable. This is
probably not toxicity in the usual
sense any more than excessive effect is toxicity, but is an extension
of the phamacologic properties of
these rapidly and potently active
diuretic agents. Excessive effect was
considered earlier.
Ethacrynic acid, then, is also a
potent, highly-effective diuretic. It
continues to be active in the face
of electrolyte derrangements and
azotemia. It is available for intravenous use and probably has a
real place in the treatment of the.
patient with acute pulmonary
edema in addition to our usual
measures.
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Fig. 8-Urine volume (cumulative) following intravenous administration of
ethacrynic acid in a patient with acute pulmonary edema occurring in the course
of chronic congestive heart failure.

Triamterene and Amiloride

Turning now to agents that act
by entirely different mechanisms,
triamterene (Dyrenium), now
available, and amipramizide or
amiloride (Cholectril) (MK-870) ,
not yet available, are shown in
figure 10. The similarity in the
structures is evident. There is a
considerable difference in the potency as triamterene is given in
doses of 100 to 200 mg and amiloride is given in doses of 5 to 30
mg. These are the agents which act
to block the sodium-potassium exchange mechanism in the distal
tubule. This is totally different
from any of the activities of the
other two agents described above.
They are similar in effect to spironolactone, but spironolactone is a
competitive inhibitor of aldosterone
and is thus only effective in the
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Fig. 9-Response to graded doses of ethacrynic acid in a patient with diureticresistant chronic congestive heart failure.
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presence of aldosterone. These
agents block this tubular reabsorptive mechanism regardless of whether aldosterone is present. In this
way they tend to be more effective
and do not require that the patient
be in a state of induced hyperaldosteronism.
One can then predict the diuretic
response. Figure 11 depicts a modest increase in sodium excretion
and a decrease in potassium excretion in response to triamterene. Essentially a maximal effect results
from a dose of about 100 mg of
triamterene. These agents are modest in their naturetic effect.
Something of the toxicity is
noted in table 5. Again rare hypersensitivity and dose related nausea
and vomiting are listed. Azotemia
has been interesting in that slight,
but significant increases in blood
urea nitrogen have been recorded.
They tend to stabilize and have not
generally been a cause of significant concern. The problem with
these agents is the development of
hyperkalemia. When given either
alone or in conjunction with thiazides, triamterene and amiloride
may cause serious and even fatal
hyperpotassemia. There is no way
to predict in a given patient the
exact response. Potassium levels
must be checked in patients receiving such therapy.
In summary, these two agents,
triamterene and amiloride have a
modest natriuretic effect, about onehalf to one-fourth that of the thiazides. They cause potassium retention, and most importantly, they
are additive in effect to the other
diuretics, thiazides, furosemide, and
ethacrynic acid. Figure 12 illustrates this additive effect. This is
the same resistant patient (fig. 9)
treated on an out-patient basis receiving furosemide. Note that 40,
80, 160, and even 240 mg of furosemide per day was associated
with no significant weight loss. At
this point triamterene was added to
this steady regimen, and the patient achieved a weight loss of approximately a pound per day over
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the next two weeks. These agents
have not been shown to induce hyperglycemia or hyperuricemia and
may have some special advantage
in patients in whom these are problems.
Some of the typical effects of
differing types of diuretic agents
can be noted in the results of a
study we have done.* Twelve patients with chronic congestive heart
failure, hospitalized on our metabolic ward on constant sodium and
fluid intake, were each given ethacrynic acid, triamterene and hydrochlorothiazide. Each patient received all three drugs, one on each
of three successive days. The order
of administration was so randomized that each drug was given with
equal frequency on the first, second, and third days. 100 mg of
each diuretic was given at 8 AM
and again at noon. Carry-over effect was minimized since 20 hours
separated the successive drugs.
Statistical analysis indicated no
significant variation due to the order of drug administration or to
the pattern of individual patient response. There were, however, statistically significant differences in
the responses to the three diuretics.
Ethacrynic acid effected a significantly greater weight loss, natriuresis, chloruresis, and diuresis
than did hydrochlorothiazide or
triamterene and did so in both the
first four hours and for the 24
hour period (fig. 13). Hydrochlorothiazide resulted in a somewhat
greater diuresis, natriuresis, and
chloruresis than did triamterene,
but these differences were not statistically significant at the 5 % level
of probability.
On the other hand, triamterene
resulted in significantly less kaluresis than either ethacrynic acid or
hydrochlorothiazide. The potassium
excretion with the latter two was
not significantly different.
This study, then, substantiates
the greater potency (diuresis, salu-
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Fig. 12- The additive effect of triamterene and furosemide in a patient with
diuretic-resistant chronic congestive heart failure.

* Proctor, J. D ., and A. J. Wasserman, to be published.
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resis) of ethacrynic acid and the
potassium sparing effect of triamterene. In this study, furthermore,
ethacrynic acid effected the most
favorable sodium-to-potassium excretion ratio, viz for each milliequivalent of potassium lost, etha·crynic acid caused the greatest loss
of sodium (fig. 14). Stated conversely, less potassium was lost for
each milliequivalent of sodium excreted with ethacrynic acid than
with either hydrochlorothiazide or
triamterene.

Summary

There are now a number of different classes of diuretics with different pharmacologic effects. Sev-
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era! considerations dictate the
choice of diuretic:
1. The responsiveness of the patient is of prime importance. If
the patient is not known to be resistant to diuretic therapy, thiazides
should be tried first.
2. The danger of alterations of
volume and of electrolytes in the
specific patient must be considered .
Patients receiving digitalis will be
subjected to much greater danger
by the induction of hypokalemia
than patients not receiving cardiac
glycosides.
3. The pharmacologic effects of
the specific diuretics must be understood for now the physician
has available agents of differing
potency, efficacy, and especially
differing mechanisms of action.
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Iatrogenic Disorders
ROBERT H. MOSER

Department of Medicine, Brooke General Hospital,
San Antonio, Texas

The contemporary physician and
his patient are riding the crest of
the most dramatic expansion of
medical capability in history. But
the rapid proliferation of medical
knowledge has not been entirely
benign. Although our reverses have
been minor in contrast to our advances, negative effects cannot be
ignored. My discussion involves
one aspect of this problem-the
emergence of what I have called
"Diseases of Medical Progress"
(Moser, 1964) .
Pertinent to the evolution of
medical capability has been the
improvement in quantity and quality of drugs. In the early days new
drugs came in a trickle, and there
was time for the physician to become familiar with their virtues
and idiosyncrasies. Soon the trickle
became a stream, and there was
less time for study and reflection.
The stream has now become a torrent; it is impossible for the physician to keep pace. His little black
bag runneth over.
It has been said that druginduced adverse effects are the
price we have to pay for more
effective medicaments (Zbinden,
1964). There can be no quarrel
with this statement; it is the high
price we are haggling about. The
thalidomide disaster indicated how
expensive it can be.
The deluge of new drugs has
produced widespread discontent
with empiricism in therapeutics.
The modern practitioner demands
drugs with proper credentials. This
has precipitated a virtual renaissance in drug investigation, and
MCV QUARTERLY 3(2) : 9 1-100, 1967

thus we have come to learn more
of the wonders and hazards of contemporary therapeutic agents.
The demands of the clinician to
know more about drugs are being
met by increasing capability in the
laboratory. New insight and appreciation of the complexities of
drug effects have come from several diverse avenues of investigation. The wedding of percutaneous
biopsy and electron microscopy
has resulted in dramatic revelations; the mysteries of intracellular morphology and physiology in
the living organism have begun to
yield. Often, we are able to observe the specific site of drug action within the cell.
In other areas techniques continue to be perfected for assay of
blood and tissue levels of drugs,
intermediate products and enzymes.
The problems of adverse drug effects are many. Reduced to simplest elements, when Drug "A" is
introduced into the body, ultimately it or its intermediate products will be carried in blood and
body fluids to all cells of the organism. The effects of Drug "A"
become clinically perceptible only
when the function of certain organs
is modified, either beneficially or
detrimentally, to the point of producing perceptible changes, and it
is by these phenomena that we
learn to characterize the nature of
Drug "A." As we focus attention
upon the response of a specific
organ (or organs) to th is drug, we
are inclined to forget that Drug
"A" is also in contact with other
tissues of the organism. Effects in
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these areas are not immediately detectible, but may become manifest
clinically at a later date. Such longrange effects may never be correlated with the antecedent administration of Drug "A."
Only painstaking retrospective
analysis of many cases will uncover
a suspected denominator. Then we
must follow with a meticulously
controlled prospective study which
will involve provocative testing in
acceptable laboratory animals before we can prove that indeed it
was Drug "A" that caused the
chronic disease. The problems of
extrapolating this data to humans
are evident. This is a shadow world
of pathophysiology where relation
of cause to effect is at best difficult
to assess. I need only cite the still
raging controversy over phenacetin and renal disease to demonstrate the difficulty. There are other
problems.
What is known of the role
played by drugs in predisposing the
organism to attack by micro-organisms or degenerative disease? An
example is the effect of long-term
corticosteroids in predisposing the
leukemia or lymphoma patient to
systemic fungus infections.
We are hearing more about the
so-called "opportunistic organisms"
- perhaps a semantically poor euphemism. But it is appropriate to
our thesis to mention Candida albicans (Seelig, 1966). This is a
saprophyte of limited pathogenicity
under normal circumstances, but
may emerge as a systemic infection
and seed into many organs during
or following broad spectrum antibiotic administration, with or without concomitant corticosteroid or
immunosuppressive therapy. This
phenomenon has been related to
suppression of susceptible enteric
flora with disruption of the normal
ecologic balance permitting the unsuppressed saprophytes to proliferate and escape their enteric confines.
The devastating influence of prolonged corticosteroid therapy upon
the elderly patient immobilized by
cardiovascular disease or arthritis,
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in whom accelerated demineralization occurs through corticosteroid
anti-anabolic effect, is an example
of exaggeration of degenerative disease caused by a drug. We start
with one disease and our treatment
for it produces another disease.
Let us modify the question again.
What is known of the effects of
drugs upon a previously diseased
organ, with limited capability to
metabolize or detoxify or otherwise
cope with a drug given to treat
another illness? I have mentioned
the phenacetin controversy. The
discussion here revolves around the
status of analgesic compounds in
the provocation of interstitial pye.lonephritis in a normal kidney. But
what effect do phenacetin, aspirin,
or the combination have upon a
sick kidney, already poorly disposed to resist assault from either
micro-organism or nephrotoxic
drug?
Consider the patient with subclinical hepatic disease, e.g., a mild
cirrhosis, who is given chlorpromazine or phenylbutazone, drugs
known to be occasionally toxic to
the liver. One could cite multiple
examples wherein an organ with
marginal function may be further
insulted by a drug administered,
most innocently and with proper
indication, to treat another ailing
system.
Pharmacogenetics and Enzyme
Induction

Perhaps the most fascinating
corollary to these observations is
the identification of a relationship
between enzyme systems and drug
effects. Vogel (1959) introduced
the term "pharmacogenetics" into
clinical medicine. This was defined
as "the study of genetically determined variations that are revealed solely by the effects of
drugs." The genetic variation results in the absence or insufficiency
of certain enzyme systems. This
mechanism has already been cited
as one major explanation of the extraordinary human variability in
response to conventional doses of

conventional drugs (Evans, 1963).
The historical and classical example of a pharmacogenetic disease is the hemolytic anemia suffered by some members of certain
ethnic groups, specifically, Mediterranean basin dwellers and Negroes
(Berry, 1965; Beutler et al., 1955).
Brisk hemolysis may follow exposure to many common therapeutic agents (among these are the
4-aminoquinolines, certain sulfonamides, acetylsalicylic acid, the nit r of ur ant o ins, sulfones, paraamino-salycylic acid, phenacetin
acetanilid, probanthine and the
water soluble analogues of vitamin
K). Even the Fava bean apparently
provokes hemolytic anemia on the
same basis.
The cause is a genetically transmitted defect that results in deficiency of the intra-erythrocytic
enzyme, glucose-6-phosphate dehydrogenase. Such patients are normal clinically; they have no morphologic or physiologic abnormality
of their red cells, until one of the
provocative drugs is given. Then
brisk hemolysis occurs. Deficiency
of glucose-6-PD has been cited as
one cause of neonatal jaundice. It
is somewhat of a problem in the
chloroquine primaquine anti-malarial prophylaxis program in Southeast Asia (personal communication, Col. Marshal McCabe).
Other red cell enzyme deficiencies of greater subtlety have begun
to emerge; these include aldolase,
catalase, glutathione, glutathione
reductase, pyruvate kinase, triose
phosphatase and isomerases.
In addition, kernicterus of the
newborn is related to immaturity
of the neonatal liver. This organ is
deficient in glucoronosyl transferase and, therefore, unable to conjugate bilirubin. Administration of
sulfisoxazole (Gantrisin) or vitamin K analogues exaggerates this
reaction. Novobiocin may provoke
jaundice in the newborn and rarely
in adults by direct inhibition of
glucoronosyl transferase (Moser,
1967, in press).
Do these adults have a marginal
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deficiency of this enzyme which
becomes evident only when they
are challenged with novobiocin? Is
it congenital, or is it acquired as
the result of a preceding episode of
hepatic disease?
There are other equally fascinating pharmacogenetic diseases.
Hemoglobin Zurich (Frick, Hitzig,
and Betke, 1962) is an example. If
a certain Swiss family had not been
given sulfonamide drugs, it is quite
likely that this abnormal hemoglobin disease would have continued
to escape detection. A frank hemolytic anemia developed after administration of sulfadimethoxine and
sulfamethoxypyridizine (Kynex) to
family members. A new hemoglobin with electrophoretic mobility
between A and S was identified;
fingerprints of peptic digests revealed three unusual peptides.
Time permits only a brief glance
at other equally fascinating pharmacogenetic disorders.
( 1) Hemoglobin H disease : patients with this illness have hemoglobin which is a tetramer of four
beta chains. Their erythrocytes appear normal until they are given
sulfisoxazole ; then a brisk hemolytic anemia may develop.
(2) Patients may be divided into
phenotypes on the basis of their
ability in inactive isoniazid (Porter, 1964; Editorial, S. African
Med. J., 1964). There is reason to
suspect that isoniazid polyneuropathy is more common in "slow inactivators" than "rapid inactivators." Fortunately there 1s no
difference in therapeutic responsiveness to isoniazid, and the development of resistance by the
tubercle bacillus to isoniazid is
similar in the two phenotypes.
(3) About 1 % to 2% of patients have a genetically determined
deficiency of pseudocholinesterase
(Hodgkin et al., 1965) ; This may
be qualitative or quantitative. The
malady will remain asymptomatic
and undetected unless the patient
is challenged with suxamethonium.
Then the response is dramatic; a
2 to 3 min period of apnea will

ensue. Pseudocholinesterase is required to metabolize suxamethonium.
( 4) It is suspected that increased susceptibility to dyskinesias
subsequent to administration of
phenothiazines such as chlorpromazine, may have a genetic basis.
And in view of the multitude
of known enzyme systems, as well
as those suspected but not as yet
identified, one could predict that
many reactions now classified as
idiosyncratic or hypersensitive will
soon be gathered into the fold of
pharmacogenetic disorders or acquired enzyme insufficiencies.
A related phenomenon is druginduced inhibition of the metabolic
breakdown or release of albumin
binding with escape of free drug.
This is epitomized by the potentiation of coumarin drugs by several rather common agents, such
as phenyramidol (Carter, 1965) ,
acetyl salicylic acid, tetracycline,
streptomycin, D-thyroxi ne, androsteneolone, phenylbutazone (Eisen,
1964) and oxyphenbutazone (Fox,
1964).
Now there is a new dimension,
quite antithetical to the concept of
enzyme deficiencies unmasked or
inhibition of metabolic breakdown
caused by drugs. This is the· phenomenon of "enzyme induction,"
in which the administration of one
drug accelerates the metabolic
breakdown of another. (Burns, et
al., 1965; Conney and Burns, 1963 ;
Fouts, 1963) . Clinical suspicion
was aroused when it was discovered that some patients receivil)g
coumarin drugs required increased
doses to maintain therapeutic anticoagulant levels while taking barbiturates.

Residual Drug Effects
Residual drug effects re.main another enigmatic area. For example,
reserpine continues to exert its
influence jn certain patients for
several weeks after it has been discontinued. It may cause unpredictable responses to general anesthe-

sia. Reserpine may obscure the
phentolamine (Regitine) test for
pheochromocytoma for several
weeks after it has been stopped.
The persisting and even progressive
retinal damage induced by residual chloroquine has been the subject of much commentary.
Elevated levels of protein bound
iodine were found in the sera of
women who had received iophenoxic acid (Teridax, a cholecystographic medium) six to seven years
previously. Babies born several
years after their mothers had ingested iophenoxic acid had extremely high levels of protein
bound iodine (Goss and Dickhaus,
1965). These agents may lie dormant in fat depots for many years,
apparently innocuous, but in curious contradiction to the usual tendency of an organism to rid itself of
foreign substances. What other
drugs are "stored" for prolonged
periods? Do they exert adverse effects? Questions come easily; answers do not.
An equally fascinating new aspect of drug mechanisms is revealed
in the recently recognized phenomenon of transferable drug resistance. This was first observed in
Japan in 1959 during studies on
Shigella which proved resistant to
several anti-microbial agents. It is
now recognized that Shil!ella and
Salmonella are capable of genetic
transm1ss10n of drug resistance
(Smith, 1966). It has been suggested that the widespread use of
antibacterial drugs in agricultural
feeds has contributed to this problem . To my knowledge genetically
transferred resistance factors have
been identified only in gram-nel!ative micro-organisms and acid-fast
bacilli.
Now that we have seen something of the broad introductory
area of drug-induced diseases, a
logical question might be: What
will be the ultimate effect of these
new therapeutic endeavors? The answer must lie somewhere in the interface between philosophy and
physiology.
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The evolution of man is a continuing source of wonderment to
students of physiology. Through
the centuries of painful metamorphosis, each challenge thrown at
man by his environment was met
by a gradual genetic modulation
that enabled him to survive. The
species has arrived at the current
state of advanced physiologic capability-admirably adapted to its
environment. We can dig diamonds
at 9,000 feet in 123° heat and
100% humidity; we can spend a
lifetime mining tin at a 14,900-foot
elevation, we can hike across the
pole, and we can float weightlessin-space for 14 days.
But in the past few decades we
have devised techniques unprecedented in the previous experience
of the species to challenge the
adaptability of the organism. We
have designed molecules unique to
human physiology and have intruded them into blood and tissue
by techniques that are also unique
in physiologic experience. Intravenous, intramuscular and subcutaneous injections, positive pressure inhalation, rectal administration, and
agents that facilitate passage
through intact skin all are unfamiliar modes of gaining access to the
body. Add, for example, radiation
by x-ray, beta ray, gamma ray and
neutrons, plus oxygen under greatly
increased barometric pressure, and
one begins to appreciate the magnitude and genius of man's conspiracy to by-pass the conventional
avenues for introducing new environmental factors to the physiology
of man.
In the past we only had to cope
with nature and environment. And
they were confined to the gastrointestinal tract, lungs and occasionally the abraided skin to admit
alien materials to the core of man.
The implications of these ingenious tactics of assault, these strange
man-made chemicals and emanations upon the beleaguered human
mechanism are fascinating to contemplate. One could speculate that
this incredibly resilient physiologic
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machine of ours is sufficiently advanced in design to be able to cope
with all transgressors. We have
evolved defenses at all levels from
the simplest reflex to the most complex immune reactions to meet the
daily challenges of environment.
And we have done very well in the
matter of self preservation.
Yet it is quite evident that some
of these unprecedented therapeutic
intrusions will overtax the ability
of the body to accommodate, and it
will react with displeasure, if not
violent rejection. Of course this is
the heart of our thesis, drug-induced diseases.
Every new drug must be evaluated for efficacy and toxicity, and
this is not an easy task. Only passage of time and acquisition of experience will determine the ultimate
verdict. Firm pronouncements
based on animal experimentation or
fragmentary early clinical trials are
premature and meaningless. Often
it takes years before the full spectrum of efficacy or toxicity of a
drug becomes evident. This poses
an almost insoluble conundrum. If
we are timid and withhold the drug,
how will we ever gain the necessary
clinical experience? If the agent is
effective and safe, it would seem
unfair to withhold it. But if the
drug is ineffective or toxic, it would
seem equally unfair to use it on patients. All that one can propose is
prudence, caution, and reservation
of final judgment until objective
studies are completed.
In an effort to dramatize the
problem of drug toxicity, I have
selected one group of drugs, the
tetracyclines, to serve as a prototype to illustrate the continuing
challenge that faces the medical
profession in arriving at a comprehensive appreciation of the spectrum of toxic effects of drugs. One
might select almost any popular
drug to do the same thing. This
could properly be called the evolution of the toxic profile of a drug.
Tetracyclines are valuable therapeutic allies. They qualify as antibiotics of choice in a host of in-
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fectious diseases. So let it be
established at the outset, there is no
denying the efficacy of tetracyclines
in clinical medicine.
Included in this group of drugs
are chlortetracycline (Aureomycin)
oxytetracycline (Terramycin), tetracycline, tetracycline phosphate
and rolitetracycline.
Chlortetracycline was introduced
in 1947. Despite the wearisome
flurry of superlatives that attends
the introduction of every major
new drug, chlortetracycline was
found to be remarkably effective.
By 1949, a reflective review of the
literature on this drug stated "it
is an important landmark in the
field of antibiotics. Its extremely
low toxicity and wide range of activity and absorbability from the
gastrointestinal tract combine to
make it a powerful therapeutic
weapon" (Rose and Kneeland,
1949). A prodigious literature extolling its virtues soon accumulated.
Early adverse effects were minor.
They could almost be characterized
as annoyances, and they were confined to the gastrointestinal tract.
Loss of appetite, nausea, vomiting,
flatulence, dyspepsia and diarrhea
occurred in about 10 % of patients
receiving significant doses (Pflug,
1963; Schindel, 1965; Bevelander,
1963). For several years the profession was quietly congratulating
itself on having found a new variety
of wonder drug with broad application and low toxicity. Even the
appellation "broad spectrum antibiotic" had a solid ring, adding a dimension of comprehensive coverage and confidence.
In the early 1950's slight rumblings could be heard in this therapeutic paradise. Other adverse effects related to gastrointestinal tract,
more severe than the early ones,
began to creep into clinical cognizance.
Antibiotics, especially the tetracyclines, can disrupt the normal
ecologic balance of the colon. Destruction of friendly commensals
facilitates overgrowth of organisms

resistant to the antibiotic. And, of
course, if any of these hostile bacteria escape their enteric confines
and gain access to blood or urinary
tract, they can cause significant mischief.
This alteration of bacterial flora
has been associated with stomatitis,
glossitis, pharyngitis, and black
hairy tongue, a cosmetically grotesque, but pathologically benign
condition. Also xerostomia, hoarseness, and vulvo-vaginitis were related to tetracycline treatment. In
most of these situations, disruption
of bacterial balance permitted the
fungus Monilia Albicans to flourish
in these unseemly sites (Pflug,
1963 ; Bonniot, 1964; Caruso, 1961;
Clendenning, 1965).
A corollary phenomenon was the
rare occurrence of bleeding in elderly patients with cirrhosis of the
liver. It was postulated that the
damaged liver was less efficient in
producing its coagulation factors.
Added to this was the belief that
Vitamin K synthesis in the small
bowel was inhibited by the alteration of flora incident to tetracycline
administration. But now this mechanism is strongly disputed. A final
step in this hypothetical pathogenesis was that the sick liver, already
struggling to produce its coagulation factors, had its supply of Vitamin K cut off. Therefore, no Vitamin K, no coagulation factor-and
we have bleeding. Unfortunately,
there is little evidence to support
this concept.
It was in 1958 that from the
British Isles, Germany, and Scandanavia came word that an old scourge
was revisiting us with a vengeance.
This was the granddaddy of all
gastrointestinal syndromes that tetracyclines and other antibiotics had
caused: staphylococcal pseudomembranous entercolitis (Bonniot,
1964; Caruso, 1961; Clendenning,
1965; Altemeier, Hummel, and
Hill, 1963; Nemeth, Feher, and
Szinay, 1963; Pockrandt, 1964; Sivertssen and Juel, 1958; Wegmann
and Bucher, 1964). Once the
friendly bacteria had been deci-

mated by the antibiotic, the Staphylococcus, previously suppressed by
normal bacterial inhabitants, had
gained ascendency and invaded the
colon wall. This resulted in destruction of the superficial cellular
layers, with necrosis and sloughing.
The result was a denuded colon
wall which wept vast amounts of
fluid, and death was not an infrequent consequence.
This dread complication had
been known before antibiotics, but
there was a distinct impression that
the incidence had risen significantly
with the use of antibiotics, including the tetracyclines. It was a tragic
paradox that in some instances the
antibiotics had been given in a sincere but naive effort to prevent the
development of a bacterial infection.
In the early 1960's, rare sporadic
cases were recorded describing a
variety of hypersensitivity reactions.
These included sudden cardiovascular collapse due to anaphylaxis,
(Bedford, 1951 ; Editorial, J.A.M.
A., 1965; Fellner and Baer, 1965).
Others included ecchymoses (Schoenfeld, 1964) , hemolytic anemia
(Takahashi, 1963), and dermatologic reactions (Schindel, 1965).
A related and even more curious problem was the reactivation
of systematic lupus erythematosus
(Domz et al., 1959). Some observers even reported the precipitation
of this disease de novo, following
the administration of tetracyclines
(Sulkowski and Haserick, 1964) .
This must be an unusual occurrence, since I have seen no subsequent reports.
In early 1963, a paper appeared
which described a new entity related to tetracyclines. It bore superficial resemblance to diabetes mellitus, since there was an excess of
glucose in the urine and even albumin. But closer scrutiny revealed
that amino-acids also were being
excreted. Thus it conformed to the
pattern that had only been ohserved
previously in patients with the Fanconi syndrome (Cleveland et al.,
1965; Castell and Sparks, 1965;
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Editorial, Medicina, 1965; Frimpter, Timpanelli; and Eisenmenger,
1963; Fulop and Drapkin, 1965;
Gross, 1963; Rice, Anderson, and
Clark, 1964).
It was an intriguing situation,
especially when the cases were collated and it was discovered that all
victims had ingested out-dated tetracycline. The mysterious malady
regressed about one month after
the drug had been withdrawn.
Warnings went out to physicians
and pharmacists advising them to
prescribe precise amounts of tetracycline and to admonish thrifty patients to clean out the medicine
chest. The American tradition of
family sharing of unused antibiotics
was publicly denounced.
A paucity of subsequent reports
seemed to indicate that the pharmaceutical industry had modified the
procedure by deleting citrate to obviate the problem of tetracycline
degradation. However, two recent
cases were reported in which potassium depletion was a remarkable
feature of a Fanconi Syndrome,
again induced by out-dated tetracycline.
This incident called to mind
some earlier work linking tetracycline toxicity and renal disease (Editorial, Ann. Int. Med., 1963; Mavromatis, 1965; Pulliam and O'Leary,
1964; Robins, 1963; Shils, 1963;
Solomon, Galloway, and Patterson,
1965; Wegienka and Weller, 1964;
Zimmerman and Werther, 1964).
These antibiotics tend to interfere
with protein synthesis. In patients
with poor kidney function, tetracyclines may exaggerate elevation
of blood urea nitrogen. Rarely, an
excessive sodium diuresis may
cause hyponatremia. As the kidney
disease becomes more severe and
function declines, the tetracyclineinduced problems are compounded
proportionately. Severe retention of
protein breakdown products, urea
and phosphate, resu1t in a metabolic
acidosis, and this· could cause loss
of weight, uremic symptoms, including anorexia, nausea and vomiting. Tetracycline adminstration to
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the unfortunate patient with severe
renal disease may result in exacerbation of clinical uremia; gastric
ulceration and bleeding has been
reported.
In 1963 a new dimension was
added to the tetracycline story. It
was discovered that these drugs had
a strange affinity for teeth, bones
and tumors (Benson, 1964; Cuttita,
1965; Editorial, J. Am. Dental
Assoc., 1964; Editorial, Lancet,
1965; Editorial, Nutrition R ev.,
1964; Frankel and Hawes, 1964;
Hilton, 1962; Kutscher, et al.,
1963; Kvaal, 1965; Madison, 1963;
Stewart, 1964; Swallow, 1964; Taguchi, 1963; Vickers, 1964; Wallman and Hilton, 1962; Weyman,
1965; Witkop and Wolf, 1963) . A
group of 50 young children were
receiving long-term chlortetracycline or oxytetracycline for the control of pulmonary infection associated with cystic fibrosis. Staining
of the teeth occurred in 80%.
Those given tetracyclines in early
infancy exhibited the most ·severe
discolorations.
Apparently tetracycline has an
affinity for the active growth sites
of bones and teeth; it migrates to
these areas soon after it is given,
and there it remains. A definite inhibition of normal calcification occurs at these sites of tetracycline
deposition.
In teeth this amounts to delayed
growth and intrinsic staining of
dental enamel; this may be the
commonest cause of deciduous
enamel discoloration in infants.
Perhaps equally distressing is the
capability of tetracyclines to migrate through the maternal placenta
to be deposited in the skeleton of
the fetus (Tubaro, 1964). In premature infants this could cause inhibition of bone growth. On a happier note, it must be noted that this
effect is reversible if the course of
tetracyclines given to the mother is
brief.
Other authors have suggested
that tetracyclines administered to
women in early pregnancy could
result in congenital abnormalities·in

their off-spring (Barkalaia, 1964;
Manning, 1964; Cobian, Bevelander, and Tiamsic, 1963) . The data
here was entirely inferential. This
did call to mind a paper published
in 1963, which described a strange
phenomenon in which tetracyclines
administered to six infants caused
a rise in cerebro-spinal fluid pressure with bulging of the fontanelle.
This process regressed promptly
upon withdrawal of the drug (Opfer, 1963). This is most assuredly
a rare adverse effect. I have seen
no subsequent reports of this phenomenon.
In another direction it has been
observed that some individuals who
are taking tetracyclines develop increased sensitivity to sunlight (deVeber, 1962; Kingsley, 1963 ; Saslow, 1961; Soga!, 1963; Storck,
1965; Tromovich and Jacobs,
1963). This apparently is more severe with demethylchlortetracycline,
but has occurred with others of the
group. This may take a rather
severe form on rare occasions with
actual epidermolysis.
Later a report described a young
lady who became myopic while
taking tetracycline; it disappeared
when she stopped the drug (Capperucci, 1964; Edwards, 1963).
Later a few others made similar
observations.
In 1964, Dr. Searcy and coworkers reported that tetracycline
when given intravenously interfered
with coagulation of blood (Searcy,
Simms, and Foremar, 1964; Searcy
et al., 1965). This was considered
to be a direct effect against specific
clotting factors. These patients did
not have liver disease and there
was no apparent disturbance of
Vitamin K production.
In late 1963, the New England
Journal of M edicine carried an article that described the deadly misfortunes of six young pregnant
women who developed kidney infections. They were given tetracycline intravenously in larger than
average doses by the intravenous
route. All died within 5 to 13 days
after the start of tetracycline treat-
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ment. Examination at post mortem
revealed identical changes in their
livers (Schultz et al., 1963) . Several more cases were reported subsequently (Brewer, 1965; Cairella,
Trasatti, and Becchi, 1964; Editorial, Brit. Med. J., 1964; Finn and
Horwitz, 1965; Horwitz and Marymont, 1964; Kunelis, Peters, and
Edmondson, 1965; Norman,
Schultz, and Hoke, 1964; Orentreich and Berger, 1965; Popper et al.,
1965: Wruble et al., 1965 ; Wruble
and Cummins, 1965).
This episode was climaxed by a
formal statement by the American
Medical Association, Council on
Drugs. "Tetracycline given intravenously should be prescribed with
caution in women in the last trimester of pregnancy. When administered, its concentration in serum
should be controlled and liver function tests should be made at frequent intervals. Finally, it is important that physicians refrain from
prescribing other potentially hepatotoxic drugs concomitantly" (Dowling and Lepper, 1964) .
This appeared on April 20, 1964.
It was a conservative statement at
the time. Today we have other
drugs with the same area of effectiveness as tetracyclines, but with
no known toxic effect upon the
liver.
And all of this is not over. Just
a few months ago an article appeared describing thrombocytopenia
related. to tetracyclines (FDA Reports, 1966). And this was almost
20 years after the first clinical experience with this group of drugs.
Again I wish to emphasize that
tetracyclines are valuable antibiotics. I prescribe them; all of us do,
but they are not entirely benign
(Moser, 1966). And it has taken
almost 20 years to appreciate this.
One may ask, how can it be that
it takes so lon{?? The answer is
not easy. I can cite my own experience .with another drug. Soon after
it appeared on the market, I prescribed Serpasil for a patient. Soon
she complained of paresthesias and
tremors.

I searched the literature; there
was nothing. I considered this a
neurotic manifestation, patted my
patient on the head, and persisted
in my naivete and ignorance. Finally symptoms became more severe; I stopped the drug; symptoms
regressed. I started the drug again;
symptoms recurred. At least I was
convinced. The patient (who happened to be my wife) was also convinced that I was an idiot. And
one week later the first article appeared on Serpasil-induced tremors.
This is not an uncommon experience, and that is why it often takes
20 years.
Conclusion

"Diseases of Medical Progress"
will be with us forevermore. They
cannot be swept under the rug,
either by clinician or drug producer. My own naivete in the world
of commerical enterprise is revealed
by my admission that I think a fine
new drug will become known to the
profession on the basis of its merit.
I am embarrassed when this noble
community is demeaned by merchandizing techniques, however
subtle or artful, better suited to less
vital products, such as soap or soda
pop. The fact that over . $750 million is spent each year for drug advertising is a staggering testimonial
to the enormity of this effort. This
is almost three times more money
than is required to run all of the
medical schools in this country for
one year. I do not feel that drugs
should be propagandized to the
medical profession. The pressure of
commercial competition is not conducive to objectivity in the presentations' of drug detail men or in
published advertisements. ·I · feel
these factors add to the confusion
in the already .difficult prob lems of
evaluating the efficacy or adverse
effects of new drugs.
The requirement for a'n impartial
agency that can provide current,
reliable and objective data ·about
the characteristics of riew drugs,
and alert the physieiari to their
0

toxic hazards is abundantly evident. This requirement has been
met by the American Medical Association Council on Drugs, which
created a national "Registry of Adverse Reactions. " A comparatively
new facility, it was the natural successor to the "Registry of DrugInduced Blood Dyscrasias," a most
successful pioneer study guided and
nurtured by Dr. Maxwell M. Wintrobe and Dr. Charles Huguley.
The new, broader registry makes it
possible for any physician to contribute his personal experience with
adverse drug effects to a central
pool. This information is recorded
on a form designed for automatic
data processing. The data are extracted and recorded in the memory
banks of a computer system.
Volunteer teams of nationally
recognized specialists study all information submitted to the Registry. Thus, the input from physicians throughout the country is
evaluated and recorded . Hopefully,
for the first time, we have the
means to obtain realistic incidence
data about adverse drug effects.
The response from hospitals and
private physicians has been disappointing, in quantity and quality
but the program is young, and already the Journal of the American
Medical Association has carried
several brief pertinent articles describing recently discovered adverse
drug effects and summarizing drug
information derived from this new
facility.
The Federal Drug Administration has inaugurated a similar program that complements the AMA
Registry and expands the total data
gathering capability. FDA concern
in the matter is oriented somewhat
differently from that of the AMA.
Nevertheless, such activity in the
nation's highest medical councils
indicates the growing importance
of adverse drug effects.
The AMA Registry represented a
significant step toward meeting the
challenge of new responsibility that
accompanies increased capability.
Our remarkable therapeutic arsenal
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is a tribute to the commercial drug
industry and the devoted chemists
and pharmacologists of our medical
schools. But neither medical
schools, AMA, FDA, nor the industry
can solve the problem completely.
My plea has been, and is directed
to the physician on the firing line,
the doctor who prescribes the drug.
It is farthest from my intention to
suggest therapeutic timidity or homeopathy. Our predecessors in
medicine had limited diagnostic and
therapeutic resources. The complement of nostrums in their little
black bag was austere, but these
drugs were regarded as old familiar
friends. Some were worthless, others dangerous; some were impure
and unstandardized to the point of
unpredictability. The few effective
drugs were trusted allies whose
strengths and weaknesses were well
known. The practitioner of the past
attempted to compensate for lack
of material resources with meticulous attention to his patients, personal charm, kindness, and pervading equanimity.
His lonely hours of private hell,
tormented by his inability to come
to grips with most of the severe illnesses that he encountered, constitute a long, bleak chapter in
medical history . The modern physician is afforded rare glimpses of
this agony when faced with malignancy or degenerative disease or
neurologic illness. Modern pharmacology has brought this unhappy era to an end; we now enjoy
the privilege of fine, powerful,
well-standardi ze d therapeutic
weapons.
Now we must work to create an
atmosphere of rational caution and
critical evaluation, where each
physician will pause before putting
pen to prescription pad and ask
himself, "Do I know enough
about this drug to prescribe it?
Does the possible benefit I hope
to derive from this drug outweigh
its potential hazard?" I do not
preach therapeutic nihilism, but
rather therapeutic rationalism.
Thank you.
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The Treatment of Anxiety*
JOHN H. SCHWAB AND NANCY H. McGINNIS
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of Florida, Gainesville

Rational therapy requires accurate diagnosis. When we apply
this precept to anxiety a fundamental question arises. Is anxiety
an illness in terms of the now berated medical model which holds
that an illness has a cause, a natural history, and hopefully a cure?
Or is anxiety a basic aspect of the
human condition, an innate pattern
of response which becomes pathological when stress, induced by
physiologic and social forces, is
magnified out of proportion to the
original stimulus? If the latter is
true, then stress and social interactions are the causative factors,
the anxiety only a reaction. Logically then, the condition of anxiety can be modified by alleviating stress or changing the social
environment. Although there is no
definitive answer to this major
question concerning the nature of
anxiety, we would like to present
briefly some of the present knowledge about it.
In 1921, Freud stated: "We call
it [anxiety] an affective state, although we are also ignorant of
what an affect is." He discussed
three components of anxiety: (1)
the specific feeling of unpleasure,
(2) acts of discharge (autonomic
and endocrine functions), and ( 3)
perceptions of these acts. Although
more knowledge of biochemical
and neurophysiologic mechanisms
has accumulated since Freud made
this observation little more is
known about anxiety. Engel
( 1962) proposed that anxiety is
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the earlier of two basic biological
patterns of which depression-withdrawal is second. He says that
anxiety "includes a variety of active modes of coping with stress
which are designated the fiight-fight
patterns to indicate corresponding
behavioral aspects (Cannon, 1939).
These involve not only the biochemical and physiological preparations for flight or fight but also internal changes anticipating bodily
injury." The psychophysiology of
anxiety is neuroendocrinological,
including activity of the limbic system and the hypothalamus, which
leads to activation of the pituitaryadrenal cortical system and facilitates a wide range of metabolic
processes involved in the long-term
responses to injury (Engel, 1953;
Ingle, 1952; Selye; 1960).
Grinker (1956) characterized
the clinical manifestations of anxiety quantitatively. Mild anxiety
is consonant with alertness or vigilance; it may be automatic, and the
patient has little psychical or physical awareness of his anxiety.
Greater quantities are manifested
as episodes of recognized apprehension with physical symptoms.
Thirdly, free anxiety, which may
be episodic or continuous, is obviously neurotic. As the anxiety
becomes more severe, disorganization of function occurs.
These are the fundamental
psychiatric concepts. For the sake
of completeness we should include
that Berger (1962) propounds a
strictly organic point of view when
he says that anxiety is a "disease
of the brain." In contrast, others
see anxiety as a patterned re101
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sponse; neurotic symptoms are
learned faulty patterns of behavior
(Hall and Lindzey, 1957). ' Further, many theorists believe that
anxiety is a constructive force,
which not only acts as a danger
signal to protect the organism, but
also accounts for motivation and
monitors behavior.
In medicine, psychosomaticists
hold that excessive or sustained
anxiety produces disturbances of
bodily functions or structures
which in turn result in organic illness. Physicians find that anxiety is
a contributing factor, a correlate,
or a result of many disease states.
They are concerned with treating
patients with acute, distressing "anxiety" attacks and those with high
levels of chronic anxiety who are
difficult to work with because of
their general nervousness, irritability, fright, and erratic behavior.

Goodman and Gilman ( 1965a) :
"obviously neither drugs nor other
somatic treatment can give the
insight to the patient that can be
achieved by psychotherapy."
Psychotherapy

We like Appel's definition of
psychotherapy as quoted by Rickels (1964) : "helping people to
handle their feelings, motivations,
and behavior more appropriately."
And we should remember that
psychotherapy is one of the oldest
medical skills. The essence of
psychotherapy is communication,
and achieving the therapeutic dialogue is dependent on the relationship between the patient and the
physician~

Despite our difficulties in understanding the nature of anxiety,
awareness of it is increasing in the
Western world (Andresen, 1963;
Finn and Rusten, 1966; Rennie,
1948). Adams and Hope ( 1962)
observe: "As a clinical syndrome,
the anxiety state outranks all other
problems in general medicine."
Our studies (Schwab et al., 1966a,
b, and c) with medical inpatients
showed that 20 % to 27 % of them
had severe anxiety. These data are
in accord with Cattell and Scheier's
statement ( 1961 ) : "Epidemiological estimates vary . . . [but] a conservative consensus estimate would
probably place 20% of the American population as needing treatment for disorders in which anxiety plays a prominent role."

By listening, the therapist tries
to obtain understanding, not necessarily agreement but rather comprehension. Either sympathetic
agreement or antagonistic disagreement may produce distortions and
solidify the neurotic organization.
Thus, the task of the therapist is,
in Wahl's words (1962) " . . . to
convert apprehension to comprehension."
From awareness of his problems comes clarification; the patient is better able to make more
appropriate decisions about his
life. Other fundamentals of psychotherapy are the educative and the
manipulative, deriving from increased knowledge of self and environment.
Just as communication is the
essence of psychotherapy, self esteem is the fulcrum on which success balances. Only with increased
self esteem can the patient order
his world and create healthful relationships with it.

Treatment

Medication

The effective treatment of anxious patients hinges on the combined benefits of psychotherapy
and medications. The limitations
of psychotherapy are well known,
and the limitations of drug therapy
have been aptly expressed by

Medication is the second component of treatment. When tranquilizers were first introduced, it
was feared that they would render
the patient too comfortahle for
psychotherapy. Obviously, this fear
has not been realized. Available
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medications do not purge anxiety,
but they can reduce it to manageable proportions, thereby improving personal relationships, and
forestalling ego disorganization
and psychosis.
Guidelines

To obtain maximal advantages
in the use of drugs, the therapist
must adhere to certain principles.
1. Little is known about their
pharmacologic action. Most of
these agents act as weak sedatives.
The barbiturates, of course, are depressants of the recticular formation in the brain stem. The action
of meprobamate is quite similar;
although no specific site of action
has been identified. Hendley et al.
(1954) indicated, however, that it
produces some thalamic synchronization, and others have observed
slow wave activity in the basal
ganglia and limbic system. It may
interfere with centrally mediated
autonomic responses. Indirectly, by
affecting cond~ction in the limbic
system, it appears to depress the
recticular formation.
According to Goodman and
Gilman (1965b), the effects of
chlordiazepoxide (Librium) and
the related compounds diazepam
(Valium) and oxazepam (Serax)
are more ubiquitous than those of
meprobamate and the barbiturates.
Chlordiazepoxide has a central action, possible peripheral actions,
and a definite sedative effect intermediate in potency between
meprobamate and chlorpromazine.
Like barbiturates and meprobamate, in experimental animals it
blocks both conditioned and unconditioned avoidance responses.
The phenothiazines (Thorazine,
Mellaril, Stelazine) appear to produce changes at many levels: the
EEG is characteristic of drowsiness; arousal is diminished; there
are some effects upon the limbic
system and the basal ganglia; and
conditioned avoidance responses
are blocked without affecting the
unconditioned responses. Jarvik
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( 1965) states that there are "several disparate views concerning
the sedative action of chlorpromazine and its effects on the recticular system." Various investigators
contend that it depresses, that it
has a biphasic action, or even that
it is stimulating. Through its depressive action on the hypothalamus, it has strong adrenergic and
weak cholinergic blocking effects
on the autonomic nervous system,
and it acts on the endocrine system to reduce urinary gonadotropins, suppress estrous cycles,
interfere with growth, induce lactation, and decrease secretion of
ACTH.
2. The dosage must be carefully individualized. For example,
some patients respond to 1200 mg
of meprobamate per day, whereas
others receive little benefit unless
that is doubled. This is even more
true of the phenothiazines; some
patients improve on 100 mg of
chlorpromazine in 24 hours,
whereas others require many times
that amount.
3. They provide only symptomatic relief by damping reactions
and quieting inner turbulence.
Thus they are only adjuncts.
4. They are not remedies for
psychosocial distress. Too often
tranquilizers are prescribed for the
treatment of sociocultural dilemmas; obviously when used for these
purposes the results will be poor.
5. Negative effects occur. Some
patients react poorly to one or all
of the antianxiety agents. Paradoxical reactions, to say nothing of
side effects, are reported for meprobamate, the
benzodiazepine
compounds (such as Librium), and
the phenothiazines.
6. Knowledge of the patient's
personality is essential. DiMascio
and Klerman ( 1960) concur with
the almost universal recognition
that the personality of the subject
and his psychophysiologic state are
important modifiers of drug action.
Many anxious patients cannot tolerate a slowed-down feeling; it results in clinical depression for

some and a loss of required motor
activity for others. Importantly,
Rickels ( 1964) has described the
effects of the barbiturates as producing more improvement in lower
socioeconomic patients who have
low drive levels, low ambition,
highly compliant behavior, and a
strong passive-dependent character
makeup. In the more intelligent,
less dependent, less compliant and
socioeconomically higher patient,
the barbiturates are less well tolerated, producing more sedation
and less improvement.
7. The physician should restrict
his use of the countless sedatives
and tranquilizers available to only
a few, so that he can become familiar with their indications, side
effects, and contraindications.
Sainz ( 1964) states : "The rate at
which new psychopharmacologic
agents appear and old ones disappear attests only to their relative
ineffectiveness." We advocate that
one should switch to a new drug
only when it has been proved
demonstrably superior. Among the
phenothiazines, chlorpromazine is
still the standard against which
others are measured. And, meprobamate and chlordiazepoxide have
been used for so many years with
so many patients that their effects
and side effects are well known.
Clinical States
In practice, patients are seen
with various anxiety states, which
can be conceptualized on two dimensions: the first is the continuum from conscious to unconscious awareness of causes and
dynamics; and the second is severity, ranging from the stress reaction, which may be mild, to the
extreme anxiety manifested by the
schizophrenic patient who is undergoing ego disorganization.
( 1) The acute stress reaction is
evidenced clinically by: agitation,
restlessness, autonomic symptoms,
insomnia, and visceral dysfunctions. Conscious elements are predominant; i.e., the patient is aware

of his tension and is able to describe its causes and effects. The
severity is commensurate with the
degree of trouble the patient is encountering. The ordinary dilemmas
of human existence, i.e., problems
of work and family, are the most
common causes.
Psychotherapy should be directed toward helping the patient
resolve the environmental stress or
removing him from it. Medications
may be necessary, but in these instances they should be given for
only a short time because their
chronic use may produce just
enough relief that the patient, instead of seeking resolution, remains helplessly and symptomatically caught in a stressful situation.
Barbiturates, either sodium amytal
or butabarbital (30 mg three or
four times a day), are useful.
Sometimes adequate sedation at
bedtime suffices. Of course, barbiturates have drawbacks: sedation, addictive properties, and possible use for suicide. Meprobamate
( 400 to 800 mg three times a day)
is obviously preferable when there
is any risk of suicide.
(2) Although acute anxiety attacks usually appear as discrete
clinical syndromes, the patient is
relatively unaware of the precipitating events and the dynamics. He
displays overt apprehension and
the symptoms of autonomic nervous system imbalance. He complains of severe dread, a fear that
he is dying, or that he is affiicted
by a terrifying condition. The
physical symptoms include headache, an inability to concentrate,
rapid heartbeat, shortness of
breath, gastrointestinal distress, bizarre sensations, and generalized
motor hyperactivity. Also, he may
be hyperventilating, complaining of
tingling of the extremities and
sharp twitches of pain in the chest,
and showing signs such as pallor,
profuse sweating, and muscle
spasms.
Clarification of the patient's
physical status usually terminates
the acute attack, but seldom pre103
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vents its recurrence. When these
patients are first seen the physician
should explore possible causes incisively. If the anxious condition
becomes chronic, the patient focuses on his symptoms so completely that his awareness of other
stresses diminishes and valuable information cannot be obtained. Because these patients are suffering
and frightened, they accept direct
questioning about the quality of
their interpersonal relationships,
stresses at home and work, sexual
activities, basic fears regarding
adequacy, etc. Psychotherapy is essential because the patient is unaware of the dynamics and usually
of the precipitating events.
Intravenous sodium amytal (200
to 500 mg) quickly relieves the
acute attack. Meprobamate ( 400 to
800 mg three times a day) or
chlordiazepoxide (Librium) (10
to 25 mg three times a day) alleviates the anxious condition but
does not protect the patient from
recurrence. Therefore, we recommend both intensive psychotherapy
and medications. Side effects of
the antianxiety agents (meprobamate and chlordiazepoxide) include withdrawal reactions, paradoxical reactions, and allergic conditions.
(3) Chronic anxiety states are
persistent, the causes obscure, and
the manifestations multifarious.
Engel (1962) says: "The somatic
symptomatology and the physiologic changes associated with anxiety set in motion a vicious cycle
-the patient begins to fear the
onset of the next acute anxiety attack and his perception of somatic
symptoms reinforces this signal of
danger." Repeated acute attacks
thus lead to the chronic condition;
the baseline level of anxiety between attacks is raised.
Chronic anxiety is evidenced by
the patient's worried, tense appearance which is accentuated as
the day goes on and the stresses
and strains of activity take their
toll. Although the anxious patient
has difficulty going to sleep, he
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feels better in the morning. In contrast, the depressed patient is generally more apathetic in the morning and brighter in the evening.
Morbidly anxious patients are preoccupied with their mental and
physical status, speaking freely of
their symptoms, and betraying
their agitation by trembling and
tension. Although they describe
symptoms easily, they do not know
what is happening to them. If unchecked, the condition becomes
progressively more severe and
panic states develop.
Psychiatric referral is recommended. Because the condition is
both severe and chronic, medications are usually needed to help
the patient work with a psychiatrist. If the patient displays muscle
tension and agitation and if his
ego strength is reasonably good,
meprobamate is preferred. For the
patient who appears more psychiatrically ill, obsessive, and has diffuse complaints, chlordiazepoxide
(Librium) is usually more effective. For the even more clinically
ill patient who will require medication over a period of months,
phenothiazine compounds should
be used. We start with 25 mg of
chlorpromazine (Thorazine) or
thioridazine (Mellaril) four times
a day, check for hypotensive reactions, and then increase the dosage by 50 to 100 mg every few
days until the patient notices some
relief or side effects apear. The
most common side effects are dyskinesias, particularly parkinsonism and akathisia. Dystonia is seen
only occasionally. In recent years
the reports of jaundice and agranulocytosis have diminshed greatly.
Hyperpigmentation and photosensitivity as well as pigmentation of
the cornea and lens have been reported (Redlich and Freedman,
1966). Recently Hollister ( 1966)
noted that some patients taking
chlorpromazine for many years
were found at post-mortem examination to have coronary artery
changes, but this has not yet been
confirmed.

( 4) Anxiety is also evidenced
clinically by neurotic behavior and
attitudes, and a host of characterologic defenses, particularly by patients who have little awareness of
their anxiety. Interpersonal relationships suffer. These manifestations of anxiety appear so intangible that the physician is reluctant
to refer the patient for psychiatric
consultation until more obvious
difficulties appear. The neurotic
behavior includes emotional !ability, erratic and inconsistent attitudes, and impaired communication
--especially between patient and
physician. This may be so great
that the physician and his patient
are unable to agree about the
severity of the illness or the necessity for particular types of treatment.
We found that highly anxious
medical patients hold distorted
views of the severity of their illnesses, maintain negative feelings
(even flagrant dislike) for hospitalization, and distrust their physicians. They display manifold characterologic defenses: irritability,
suspicion, lack of cooperation, and
passive-aggressive activities
(Schwab et al., 1966a).
When anxiety is expressed
through these defenses, the severity
is variable; the defenses become an
integral part of the character structure so that the person lives with
the reputation of being troublesome. But more severe anxiety
states develop when he is stressed
by medical illness or one of life's
catastrophes.
In these patients medications
have little value; the defenses bind
the anxiety, and the patients consider their personality symptoms to
be ego-syntonic. Psychotherapy also
has limited effectiveness until the
patient's interpersonal difficulties
multiply.
(5) Overwhelming anxiety is a
conspicuous symptom of schizophrenic reactions, particularly the
acute undifferentiated type. These
patients show many of the classic
signs of schizophrenia: they are
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vague, their thinking is autistic and
highly personalized, ambivalence
and indecisiveness are obvious,
their affect is one of fright and
suspicion, and of course they may
be hallucinatory or delusional.
They are not aware of the sources
of their anxiety, or their description is so incoherent that they cannot communicate with others. In
the milder forms, misdiagnosis is
common. For example, Lynn
(1964) fol.ind that of 133 patients
referred for psychiatric consultations to the Indiana University
Medical Center, 34 schizophrenic
patients had been either misdiagnosed or inadequately treated.
The schizophrenic patients with
less severe disorders respond well
to psychotherapy that emphasizes
specificity, concreteness, and current realities. Phenothiazines are
the only medications which are
really beneficial. Ambulatory schizophrenic patients require 200 to
500 mg of chlorpromazine (Thorazine) per day for many months.
When the medication is discontinued it should be reduced gradually over a period of months.
(6) Newer concepts of mental
illness now recognize admixtures of
anxiety and depression. Once they
were rigidly differentiated as entities, but now we know a patient
may appear at any point on the
continuum ranging from so-called
"pure" anxiety, through complex
reactions which manifest both anxious and depressive elements concurrently, to the more classical, obvious, retarded depressive state.
Many of these patients respond
to the newer antidepressant medications, particularly those which
exert some phenothiazine-like action. Amitriptyline (Elavil) (10 to
25 mg three or four times a day)
or nortriptyline hydrochloride
(Aventyl) (20 to 100 mg daily)
are recommended. Several British
investigators (Sargant, 1962; Sargant and Dally, 1962) have reported on the successful use of
MAO inhibitors for the treatment
of patients showing anxiety as a

prominent feature of their illness;
however, we have had no experience with them in the treatment
of these patients. These various antidepressants should not be used in
combination and can be used in
tandem only if there is a 7 to 14
day drug-free interval between
them.
It is impossible to generalize
about psychotherapy for these patients. Some are benefited; many
are not. Each case must be individualized.
Conclusions About Drug

Therapy
Evaluating the tranquilizing
agents is complicated for a number
of reasons; the literature is filled
with inconsistencies.
First, the end result is often a
non-specific, "feeling better," which
defies quantification.
Second, selected patient samples
are used for much of the research.
In this respect, Rickels (1964)
found that conscious and unconscious attitudes toward physicians
differ greatly in lower social class
patients visiting a medical clinic,
as compared with middle social
class patients visiting a psychiatric
clinic. Moreover, the physician, usually a member of the middle or
upper social class, is better able
to understand and treat patients
with similar backgrounds and aspirations than patients from the lower
social classes. Yet, this latter group
is frequently in even greater need
of help.
Third, drug response varies with
the motivation of the subject (DiMascio and Klerman, 1960). Financial remuneration, counterphobic defenses, and wishes to
establish contact with psychiatric
personnel motivate subjects who
take part in drug studies.
Finally, most clinical trials are
conducted for only four to six
weeks. We have found that many
anxious patients will improve on
any medication during the first few
weeks. Yet many reports of the ef-

ficacy of these medications are derived from such brief studies.
Notwithstanding these difficulties, when properly used, the psychopharmacologic agents have benefited many patients. And, just as
importantly, the use of our relatively crude compounds of the
1960's lends hope that we are just
on the threshold of a biochemical
and psychopharmacologic era in
which our knowledge of the physiology of the brain will become exact, the mechanics underlying
mental illness will be revealed, and
definitive drugs for treatment will
be found.
References
A.DAMS, R. D., AND J. HOPE. The
anxiety state and psychasthenia. In
Principles of Internal Medicine.

T.R. Harrison et al. New York:
McGraw-Hill, 1962, pp. 390-397.
ANDRESEN, A. F. R., JR. A practical
approach to anxiety reactions. N . Y.
State J. Med. 63: 1144-1147, 1963.

BERGER, F. M. The treatment of
anxiety: A critical review. J. Neuropsychiat. 4: 98-103, 1962.

CANNON, W. B. Bodily Changes in
Pain, Hunger, Fear, and Rage. New
York: Appleton Century Co., 1939.
CATTELL, R. B. AND I. H. SCHEIER.
The Meaning and Measurement of
Neuroticism and Anxiety. New
York: Ronald Press, 1961.
DIMASCIO, A., AND G. L. KLERMAN.

Experimental human psychopharmacology: The role of non-drug
factors. In The Dynamics of
Psychiatric Drug Therapy. G. J.

Sarwer-Foner (ed.) Springfield:
Charles C Thomas, 1960.
ENGEL, F. L. General concepts of
adrenocortical function in relation
to the response to stress. Psychosomat. Med. 15: 565-571, 1953.

ENGEL, G. L. Psychological Development in Health and Disease. Philadelphia: W. B. Saunders Co., 1962,
pp. 384--388.
FINN, R., AND P. E. HusTEN. Emotional and mental symptoms in
private medical practice. A survey
of prevalence, treatment and referral in Iowa. J. Iowa State Med.
Soc. 56: 138-143, 1966.

FREUD, S. The Complete Psychological Works of Sir?mund Freud. J.
Strachey (ed.) Vol. 20. London:
105

TREATMENT OF ANXIETY
The Hogarth Press, 1921, p. 132.
GOODMAN, L. S., AND A. GILMAN. The
Pharmacological Basis of Therapeutics. 3rd edition. New York:
Macmillan, 1965a, p. 160.
GOODMAN, L. S., AND A. GILMAN.
The Pharmacological Basis of
Therapeutics. 3rd edition. New
York: Macmillan, 1965b, p. 188.
GRINKER, R. R. Psychosomatic approach to anxiety. Am. J. Psychiat.
113: 443-447, 1956.
HALL, C. S., AND G. LINDZEY. Stimulus-response theory. In Theories
of Personality. New York: Wiley,
1957, pp. 420-466.
HENDLEY, C. D., T. E. LYNES, AND
F. M. BERGER. Effect of 2-methyl,
2-n-propyl-1, 3-propanediol dicarbamate (Miltown) on central nervous
system. Proc. Soc. Exp. Biol. Med.
87: 608-610, 1954.
HOLLISTER, L. E. Psychopharmacological drugs. J. Am. Med. Assoc.
196: 411-413, 1966.
INGLE, D. J. The role of adrenal cortex in homeostasis. J. Endocrinol.
(Proc.) 8: 23-37, 1952.
JARVIK, M. E. Drugs used in the treatment of psychiatric disorders. In
The Pharmacological Basis of Therapeutics. 3rd edition. New York:
Macmillan, 1965, pp. 159-214.
LYNN, G. E. Psychopharmacologic
survey of psychiatric referrals. J.
Indiana State Med. Assoc. 57 ( 11):
1229-1235, 1964.
MAY, R. The Meaning of Anxiety.
New York: Ronald Press, 1950.
REDLICH, F. C. AND D. X. FREEDMAN.
The Theory and Practice of Psychiatry. New York: Basic Books,
1966, pp. 306-346.
RENNIE, T. A. C. Anxiety states:

106

Their recognition and management.
Med. Clin. N. Am. 32(3): 597608, 1948.
RICKELS, K. The use of psychotherapy
with drugs in the treatment of anxiety. Psychosomatics 5: 111-115,
1964.
SAINZ, A. Phenothiazines in the management of stress and anxiety.
Psychosomatics 5: 167-173, 1964.
SARGANT, W. The treatment of anxiety
states and atypical depressions by
the monoamine oxidase inhibitor
drugs. J. Neuropsychiat. 3 (Suppl.
1): 96-103, 1962.
SARGANT, W., AND P. DALLY. Treatment of anxiety states by antidepressant drugs. Brit. Med. J. 5270:
6-9, 1962.
SCHWAB, J. J., N. H. McGINNIS,
L. MARDER, AND R. S. CLEMMONS.
Evaluating anxiety in medical patients. J. Chronic Diseases 19:
1049-1057, 1966a.
SCHWAB, J. J., L. MARDER, R. S.
CLEMMONS, AND N. H. McGINNIS.
Anxiety, severity of illness and
other medical variables. J. Psychosomat. Res. IO: 297-303, 1966b.
SCHWAB, J. J., N. H. McGINNIS, AND
J. D. HARMELING. Anxiety in medical patients. Presented at the Annual Meeting of the Academy of
Psychosomatic Medicine, Majorca,
Spain, Sept., 1966c. Accepted for
publication in The Proceedings.
SELYE, H. The concept of stress in
experimental physiology. In Stress
and Psychiatric Disorder. J. M.
Tanner (ed.) . Oxford: Blackwell
Scientific Publications, 1960.
WAHL, C. W. The medical management of acute anxiety states. New
Physician 11: 430-432, 1962.

The Physician as Humanist*
GEORGE T. HARRELL

Dean of Medicine, the Pennsylvania State University College of
Medicine, Hershey

It is appropriate that this lecture
should be given in a building which
is devoted to the broader aspects of
living and which is located on
the campus of an institution which
treats bodily ills. This institution
began as part of a liberal arts
college. This tradition in the state
of Virginia started with Mr. Jefferson when the University was
established at Charlottesville. He
decreed that one of the first chairs
should be in medicine, not as preparation for a professional career,
but as a discipline which should
be understood by all educated men.
The faculty at this institution has
recognized this principle, and this
lectureship was endowed by a
member of the faculty-a rather
unusual occurrence. The medical
college is continuing its interest in
this field through the ecumenical
program which is just getting
started and which is broadly based
in the health sciences as a whole.
Historical Role of the Physician

We live in a time of great change
in the world. The industrial revolution, only 200 years old, was
made possible by the harnessing
of the sources of natural power,
particularly the fossil fuels-coal,
oil and gas. At the rate we are
being so profligate with these fuels,
we can anticipate that the supply
may be exhausted in a hundred
years, if not less. We are beginning to turn to nuclear power, developed for the purposes of war,
but now being used for peace.
* The Tnird Annual Sanger Lecture, delivered at MCV, March 17,
1967.
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Even this source is not inexhaustible, and in the long run we must
look toward the harnessing of the
sun. These changes in the physical
world around us have resulted
largely from the growth of science.
We in medicine are proud of the
fact that the sciences as we know
them today began in the faculties
of medicine in the medieval universities through the efforts of
physicians to improve the care
of patients under their charge.
Roughly 90 % of all the trained
scientists who have ever received
graduate degrees in history are
alive today, and many of them
are still working. This development
has resulted in an explosion of
scientific knowledge, most of which
we use for the good of man.
Along with this change in the
physical world has been an evolution in society. Man, so far as we
know, has been on this earth somewhere in the general range of a
million years. He has been organized into civilizations for something like ten thousand years, as
best we can tell from archaeologic
studies. Before this time he moved
in groups, which were essentially
tribes. This pattern followed that
of animals, which group in herds
for mutual protection.
The family unit apparently began to evolve when man turned
from the nomadic life to an agricultural one and thus became localized in a given area. Family
units began to group together into
towns and cities. The political units
grew into nations which have been
largely determined by geographic
and economic factors. Now we are

seeing the evolution continue into
supranational organizations involving continents. Indeed, with the
rate of communication and the
ease of travel, we are coming closer
and closer to one world.
If we look at these factors in
historical perspective from the
point of view of the physician, we
recognize that, in times past, life
was short and quite perilous. The
causes of disease were unknown.
Epidemics swept across the land,
and other diseases were endemic.
Most people died of infections, and
most of those who died were children. It is likely that more than
half of the children ever born died
before they reached their fifth
year. Illness was cared for in the
home by the family with the help
of the shaman, witch doctor, medicine man, or physician. The first
physicians, so far as we know,
were probably specialized priests,
because priests were the first educated men. They made observations on natural phenomena about
them, and learned to predict the
occurrence of eclipses and other
celestial phenomena. We see. the
evidence of their accurate observations in such monuments as Stonehenge, in the temples of the Aztecs
and Mayas, and in pyramids and
other buildings in Egypt and the
Far East. Because of their ability
to predict celestial phenomena, particularly the coming of disturbing
things like eclipses, the priests were
surrounded by an aura of magic
and miracles. As the priests moved
more into the study of illnesses,
I am sure they continued to encourage the feeling of people that
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they were able to perform miracles.
Even today many physicians are
not averse to having their patients
feel that they are, indeed, miracle
workers .
As the physician evolved from
the priest, he turned his observations from natural phenomena to
human disease. The information
observed was recorded, passed on
to others, and often incorporated
into religious laws. The Old Testament indicates the Hebrews accurately observed that whenever
groups of people came together in
an army, outbreaks of dysentery
followed quickly. They noted the
cats' habit of burying their excreta,
applied this principle, and found
that epidemics could be controlled.
Each soldier was required to provide himself with a wooden paddle
and deposit his excreta outside the
confines of the camp. We now
know, scientifically, that the control is due to the secretion by soil
organisms of antibiotics which kill
the pathogenic bacteria causing
dysentery. The Hebrews also observed that, when people ate pork,
muscle pains frequently followed;
hence, they proscribed the consumption of pork by their religious
followers. We know today that the
cause of these symptoms is trichinosis, an infestation by a small,
round, parasitic worm which lives
predominantly in hogs. We see in
many religious ceremonies, such
as the communion service, the
washing of hands by the priest.
This act is a recognition that the
contamination of food by hands
soiled with excreta can pass on infections to others.
The physician in the past had
few effective drugs. All he could
do was give comfort to families
and wait for the natural history of
the disease to run its course. The
few "drugs" he had to work with
were chiefly natural products from
plants. The poppy probably has
been the most helpful plant with
its product, opium, relieving pain or
controlling increased ·gastrointestinal motility. Ipecac will alleviate
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amebic dysentery, cinchona bark
will control the chills and fever of
malaria, and the products from the
deadly nightshade or oleander will
relieve intestinal cramps. The ladies
extended these latter observations
on the effect of deadly nightshade
by chewing the leaves so that the
belladonna would dilate their pupils and thus make them beautiful.
In any event, the physician and
the priest have always dealt with
people-with the human beingand, hence, have always been humanists. Their concern is with the
interests, motivation, and reactions
of people. We recognize that each
individual is distinctly different
from another. The individual variability of all living things is a
basic biologic phenomenon. Members of families, as a group of individuals, react with each other and
react to the normal stresses of living. Families live in a community,
which has a personality, just as
people do. The community's personality is determined largely by
the cultural background of those
who inhabit it. All of these factors
affect the illness of the patient and
are felt beyond him biologically,
socially, and economically on the
family.
Medical Profession
Professions have a responsibility
to society to render service. Society,
in turn, gives privileges to a profession. The practice of a profession is restricted to its members,
and in return the profession as a
whole is required to maintain its
standards and to develop a code
of ethics. We recognize that to
practice medicine is to enter a
highly confidential interpersonal relationship and, hence, requires professional and personal integrity of
the highest order. This idea has
been expressed in various ways,
probably the best known of which
is the Hippocratic oath. But similar
statements brought up to date for
this century have been put forth,
as in the Declaration of Helsinki.

The medical profession is toserve the patient and society. In
the Christian religion, Christ taught
that we should help the sick and
not cast them out as had been
the custom in many primitive societies. Luke, the physician, was one
of the early followers of Christ.
He taught these humane practices,
which are also put into effect in
many other religions. Previously,
when people became aged and infirm or developed what was recognized as an epidemic disease, they
were put out of the tribe, just as,
animals cast the weak out of the
herd because they attract predators.
In the past, the sick have been
cared for chiefly in the home by
the family and the physician. The
priest, however, has always visited
the sick. During the crusades the
religious orders_:_particularly the
Knights Hospitalers-on their return from the Far East often came
back with leprosy, so that they were
required to stay outside the cities.
This practice led to the development of the principle of quarantine.
Because they were Knights Hospitalers, their habitation came to be
known as a hospital, and we have
kept this term to this day. The
original hospital was an isolation
unit to quarantine epidemics and to
protect society, rather than a place
to treat the sick. Later this idea was
extended by the church which took
the responsibility for providing a
place for medical care. The original nurses, as you know, were
called sisters since they were sisters
in the church. This thread of the
support of many hospitals by religious orders continues to this day.
We have seen the parallel threads
of medicine and religion continued
in the spread of our religious beliefs through missionaries who have
learned that one of the most effective ways to get the attention
and faith of primitive peoples is
to establish hospitals and to render
medical service. This pattern we
have seen exemplified most strikingly in this century by Albert
Schweitzer, who was a great hu-
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manist interested not only in re1igion but in philosophy, music,
:and medicine, though he carried
his philosophy for reverence of life
to an extreme.
In any event, we have seen
changes coming in society which
affect these trends. We have seen
increasing mobility in families, so
that one family in five does not
live in the same house it lived in
five years previously and another
-0ne in five does not live in the
same city it formerly lived in. This
trend poses an increasing problem
in medicine when the physician attempts to develop a close and continuing relationship with a family.
In addition, the family itself is
changing. In the past we saw several
generations living in the same
household, with the grandmother
helping to mind the children, raise
them, and care for their illnesses.
Now families are essentially one
generation families, and the parents
and grandparents are living in
separate households.
New Trends in Medicine

We have seen a great increase
in the complexity of the instruments
and types of machines with which
we treat sick people. We have seen
a growing centralization of medical
care in institutions as our culture
has become urbanized. This trend
poses a real danger in the loss of
the personal touch in the care of
the patient.
We have seen changes in the
character of illness. The infectious
diseases which killed the majority
of people as short a time as thirty
years ago are now largely under
contrQI. The chief causes of death
are no longer influenza, pneumonia,
tuberculosis, and the enteric infections-typhoid fever and dysentery-but are now chronic illnesses-heart disease, stroke, and
cancer. We have seen an increase
in life span, which is greater now
in women than in men. We have
learned through preventive measures, the development of drugs

and the application of new techniques of therapy, to interrupt the
natural history of disease. Science
has had a major role in causing
these changes.
In the past, the professions were
theology, law, teaching, and medicine. The education of the professions has been in the hands of the
professions, at least since the
Middle Ages. As I have indicated,
the faculties of medicine in the
medieval universities were the
places where observations on sick
patients led to studies in physical
sciences. You are familiar with the
portraits of the physician in his velvet robe and hat, holding up a
Florence flask of cloudy urine. He
began to perform simple chemical
determinations, and out of these
experiments grew the sciences of
physics and chemistry as we know
them today. In biology, the whole
science of genetics, which is probably the most interesting and exciting scientific problem facing the
world today, was started with this
thread of medicine and religion.
The accurate observations of Mendel, a monk, were made on flowers
which he grew in the monastery
garden; and the principles he developed have been applied to the
breeding of many other types of
living things. We are seeing social
and behavioral fields just beginning
to evolve as sciences in their own
right, comparable to the physical
• and biological sciences. An explosive growth of knowledge has
occurred largely as a result of research. From our point of view,
the most important scientific principle we have recognized is that of
biologic variability-the fact that
no individuals in a group are identical. No two of you look alike,
behave alike; and if we measured
any physiological parameters on
you, the data would scatter. If we
plot the data, whether height,
weight, blood pressure, blood sodium content, urinary chloride excretion or anything else, we come
out with a smooth bell-shaped probability curve. We recognize also

that the physiological measurements of an individual are variable
from day to day. To develop scientific criteria in an essentially
variable system, one must study
large groups of individuals in order
to smooth out the individual variations. The data on one individual,
when applied to conclusions drawn
from studies on a group, meet no
scientific criteria that are acceptable. This is simply another way
of saying that the practice of medicine as it applies to the individual
patient is not a science, has never
been a science, and can never be
a science.
The practice of medicine is an
art. The educational background
of the physician and his training
must take this fact into account.
What the physician does in practice is to apply scientific and technical knowledge to the solution of
an individual problem. Other professional people do the same thing.
The architect, for example, talks
to you about your sense of values,
how you want to lead your life,
what your cultural interests are,
and then he designs an individual
solution for your family, which is
your home. This process is an exact
parallel to what the physician does
when he is faced with a diagnostic
or therapeutic problem. The important thing is that, unless one
takes into account the several factors that motivate people and drive
them, one cannot be sure that the
recommendations for care will be
accepted by the patient and his
family. Many times the failure to
accept the recommendations of
physicians is due to religious, philosophic, or economic factors outside the realm of science. For
example, we need only call attention to child spacing when the
mother has advanced renal disease
and problems involving life and
death are concerned. How do we
carry these ideas over into the education of the professional man?
Historically, all professional men
received a classical liberal arts education. Today we feel that in medi109
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cine there should be parallel instruction in the sciences and in the
humanities. Whoever commits himself to a life in the medical profession has committed himself to
a never-ending process of self-education, which should be in both
disciplines. The priest has always
had a classical education, but more
and more he is becoming involved
in the behavioral and social sciences which are proving to be necessary for the practice of bis profession .
In any event, those of us in
medicine should see that we all
work together for the education of
the physician. All health scientists
and workers will be better prepared
to give patient care if they are
trained together to work better together in the community. We recognize that the sciences on which
medicine is based are not distinct
disciplines but a continuum and
that our designations are artificial
when we call one science chemistry, one biology, and another
physics. Take the simple problem
of Mendel and his colored sweet
peas, which is concerned with the
study of genetic inheritance and
the transmission of characteristics.
We know now that this transmission is accomplished by a single
chemical substance-DNA. But, if
one studies DNA from the chemical point of view of the number
of atoms and their arrangement,
he may be called a biochemist
since be uses biochemical tools. If
a person studies this compound
from the size of the molecule, its
sedimentation gradient, its X-ray
defraction pattern or uses some
other physical technique, he is
called a biophysicist. But if he
studies its effect on living things,
he would be called a molecular
biologist. In effect, each person is
studying the same chemical compound; but, the sciences are artificially separated according to the research tools applied to the solution
of this scientific problem. Hence,
in medicine, our education should
be from as broad a multi-discipli110

nary point of view as we can devise, both in the basic and clinical
sciences. If we extend this concept
beyond the student years, we recognize that the physician in practice can begin to call on other
people who have different backgrounds, such as the priest, who
also have an interest in the motivation and reactions of people
from a quite different point of view
than the physician. Hence, the
priest can be used as a professional
colleague in the care of certain
patient problems.

Current Problems
The major problems that face
the world today, in my opinion, are
not scientific, but ethical and
moral. The basic scientific information on which we could arrive at
workable solutions to these problems is largely known. We need to
refine and extend our knowledge;
but we have already learned that,
even though we accumulate additional scientific knowledge, the acceptance by people of solutions to
their problems on the basis of their
beliefs and sense of values has
not come about. Let us take one of
the very practical problems which
faces us today-the balancing of
the food supply with the growth in
the population. It does not seem
likely that, even with the application of scientific principles we
know, we can keep up with the
increase in the food supply at the
same rate as the population. We
can turn to the sea as a source of
protein; we can increase the use
of chemical fertilizers on the land;
we can increase the use of pesticides to improve crop yields. When
we do the latter, it is not without
danger; for when we use pesticides,
we are upsetting natural ecology.
We have also learned how to
control the rate of population
growth. You know about "the pill"
and the various intrauterine devices
to control conception. The acceptance of these methods by people

is determined not by scientific principles, but by philosophic, ethical,
moral, and religious values. People
in all parts of the world have
known for centuries how to cause
abortions. We are faced with the
problem-and you see it in the
newspapers daily-where the legislatures will not face revision of
archaic laws devised many years
ago before safe, scientific methods
of abortion were worked out. What
is the ethical problem if there are
known genetic factors which will
lead to handicapped children or if
there has been exposure to rubella
virus in early pregnancy? Is it
proper that this pregnancy should
be aborted?
We look at the population problem in India, where cattle roam the
streets, cannot be killed for religious reasons, and eat food which
could be used for human consumption. Yet, when any suggestion is
made by government' that the number of cattle be reduced, riots and
political turmoil follow. We have a
problem all over the world with
rats. Rats eat as much food as
human beings do, and we can control the rat population using one of
several techniques. We do not face
this problem, which is not a scientific one but rather one of inertia.
We are beginning now through
scientific means to learn how to
manipuiate genes. We have recognized that viruses and drugs can
alter the development of organs at
certain stages of pregnancy. With
this beginning, one can see coming
down the road not too many years
hence the ability by other techniques to make definite changes in
genes as one might desire. Already,
we can interfere with the natural
history of the transmission of characteristics. We see artificial insemination, started in cattle breeding,
now applied to human beings. It is
perfectly possible now for a
woman in a childless marriage to
v- select the characteristics she wishes
her child to · have. We have seen
more recently the ability to transplant an ovum from one human
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being to another. This accomplishment raises the possibility of a
sterile, non-ovulating woman picking another to furnish the ovum
which can be fertilized by her own
spouse, be implanted in her fallopian tube, and result in a pregnancy. We recognize that application of these techniques may stop
the genetic transmission of diseases which are usually fatal. Hemophilia is a perfect example in which
we know the recessive gene is transmitted only through the mother.
What are the moral and ethical
implications of these things which
we now technically can do?
We are getting more and more
into the problems of organ transplantation. What is the proper ethic
for use of this technique? We have
seen the refusal of certain religious
sects with fundamentalist beliefs to
permit transfusion of children or
-0f themselves when they need this
1ife-saving procedure. Should we
take society's power through the
,courts to require tranfusion when
it is against religious belief? What
types of people should we select
for the implantation of artificial
hearts and for the use of artificial
kidneys or dialysis machines, particularly when we know there is
an irreversible biologic process?
What is our responsibility as physi-cians to prolong life if we know
there is a hopeless illness? Is the
withholding of drugs or procedures
which could prolong life for a
while ethically and morally the
same as giving a drug which would
hasten inevitable death-euthanas ia? This problem has been debated, of course; but we have no
clear code of ethics on which to
base our actions.
We are becoming more and
more concerned with problems of
buman experimentation, since we
are learning that we cannot always
extrapolate from lower species to
the human being. This problem is
going to become more important
if legislation similar. to that passed
in the last Congress is extended.
The restrictions on the use of ani-

mals for experimentation of all
types, if continued, will require us
to go more and more directly to
the human being. We have to recognize, also, that in many types of
disease processes we have no
model which we have been able to
reproduce in lower animals. In
these instances, we must do our
primary experimentation on the
human being.
We have learned to interrupt the
natural history of disease. We have
learned to control the vectors
which transmit infectious diseases
and the reservoirs which harbor
them. We have seen the philosophy
of the reverence for life extended
in Schweitzer's hospital so that you
could not swat a mosquito even if
you saw it land on you and be
about to bite. You could not kill
the rats that were eating the food
in the storehouse. How do we interpret moral values in the light
of the world in which we live? We
have seen the development of
mood-altering agents and of penicillin, which is probably the most
important single drug that has been
developed. The mood-altering drugs
have the greatest implications for
moral, ethical and philosophic considerations, however. When we can
control behavior, as we know we
can with mood-altering drugs, what
could be done with inclusion of
these agents in food as additives?
You are familiar with the novels
that have been written on this
general theme.
What about accidents, which are
the third largest cause of death and
most frequent in the most productive years of life, between the
ages of ten and thirty? Accidents
occur in individuals whom we call
accident prone, and these accidents
appear to be examples of reactive
behavior. In any event, we need to
consider what is society's responsibility and that of the physician in
using the tools he has now at hand
in these types of problems which
he thinks may be soluble. We are
contaminating our environment, as
is written in the papers almost

daily. What is our responsibility to
prevent man from harming himself?
Educational Programs

How can we put these points
into educational programs for the
future? The ultimate objective is
the improvement of patient care.
We believe that solutions may
come in the study of the whole
man, not just of his biological
interactions, but of his functioning
as a unit of society in his family
and particularly in his community.
It is there that the stresses of living
cause him to react and produce
symptoms which we cannot medically explain. These symptoms arise
' not only from the pace and pressures of living but from the frustrations of his job and from the normal stresses that occur within
families. We think the educational
process should stress continuing
self-education of the physician
from the beginning of his professional career. We recognize that
the thread of human biology can
start with other species but must
go on to the human being. We believe that much more stress should
be placed on behavior as a basic
biologic phenomenon which is essentially variable. This study can
start with group and individual behavior in animals and then extend
into observations on man. We can
then study the added impact of disease processes through all the years
of the medical curriculum. To help
in this program, we plan at Hershey a, Department of Behavioral
Science as a basic medical science
which will teach through all the
years and serve as a base for all
the clinical disciplines.
We think there should be the
parallel thread of the humanities
through all the years of the curriculum. We have already appointed a man to our chair in
religion, and we believe that the
study of comparative religion is an
important background for any professional man in the health sciences.
Religious beliefs encompass the
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personal, intimate, and emotional
reactions of people to beliefs which
they hold. As we have indicated,
we feel that they affect the acceptance by patients and families
of the physician's recommendations for care. We plan to incorporate teaching in the history of
science to get the background on
which the profession of medicine
now rests, extrapolating into the
future what we can see coming
over the horizon. We think there
should be another chair in philosophy and ethics. Unless the physician has come at peace with
himself in a philosophy that is
satisfactory to him, he cannot be
the best physician to his patients.
We believe that the interpretation
of the changes in moral values that
we see in the world, particularly in
the community, is the responsibility
of this field. We have called this
area the Department of Humanities.
We feel the role of the family
must be studied further. We must
consider not just the care of illness
after it has developed but the prevention of disease and the delaying
of complications that we know are
coming from the genetic background of the families. We must
maintain health at its highest level
and see that people have some joy
in living. The family must be related to the community so that the
resources available in the community can be used to achieve the best
results in patient care. Accordingly,
we are establishing a Department
of Family and Community Medicine to teach throughout all the
years of the medical curriculum.
All of these programs are designed to come together at a focal
point-the patient in the family
setting. Here we hope the physician will learn to bring colleagues
in-the priest, the educator and
others. The approach should be
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from the multidisciplinary point of
view, exactly as we started with the
scientific aspects of education, but
in a broader sense. If we can capture the religious zeal that we have
had in the past in the educational
process, we can improve the care
of the sick. We should remember
the dignity of the individual and
emphasize the individual both as
a student and as a patient. We feel
these ideas can be designed into
the physical facilities in which the
educational process takes place.
With the student, it is the medical
sciences building and the hospital
where patient care takes place. We
have planned the hospital with all
single rooms for patients, where
dignity can be maintained most
easily.
We see changes in the patterns
of support, with third parties coming in to help care for the cost of
illness. But, in this trend is the
danger that more and more an
attempt will be made to substitute
an institution for an individual in
what is in essence an interpersonal
relationship-that between the patient and his physician. We are
posed here with another philosophic and ethical problem. How
much do we use machine techniques in data handling? What is
the effect of this technique on the
patient when he knows that his
data have to be made available to
a third party who is going to pay
the bills for his illness?

Conclusion

These problems are all soluble.
If we give thought to them, both
in the educational process and in
the application to patient care with
the dedication of all those working
in the health professions, we will
increase our service to people.

The Controversy Over Generic Equivalency
of Drugs
WERNER LOWENTHAL

School of Pharmacy, Medical College of Virginia, Richmond

A drug (single chemical entity)
is known by several names. First,
the chemical name describes its
structure by standard chemical
nomenclature. Second, the research
code number is assigned to the
drug during pharmacodynamic
studies in animals, and often during early clinical investigation.
Third, it receives a generic name
which is often a contraction of the
chemical name, but which describes the drug and the class of
drugs to which it belongs, e.g.,
barbital, phenobarbital, pentobarbital, etc. The U.S. Adopted Name
Council (USAN), composed of representatives from the American
Medical Association, U.S. Pharmacopeia (USP), National Formulary
(NF), and Food and Drug Administration (FDA) recommends
generic names for all new drugs.
Since 1962, the FDA must approve
all generic names. Before, 1962,
the generic names were often not
descriptive of the drug, and were
confusing and difficult to use (Wilson, 1960). Fourth, the drug receives a trademarked name (brand
name), designated by a superscript ® at the end of the name,
signifying that this name has been
registered with the U.S. Patent Office. Only the registrant may use
the trademarked name for the particular drug; thus his product is
distinguished from those of competitors.
Many older drugs that are public
domain, or on which the patent
has expired, are often best known
by the generic name, e.g., phenobarbital. If a prescriber wishes to
prescribe the phenobarbital produced by Winthrop Laboratories,
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he uses the trade name Luminal.
Tetracycline HCl is the generic
name for a specific antibiotic,
which may be purchased or prescribed by that name. It is also
known by certain trade names, e.g.,
Tetracyn (J. B. Roerig & Co.) ,
Achromycin (Lederle Laboratories), Kesso-Tetra (McKesson Laboratories). Even if a company
holds an unexpired patent on a
drug, it may be the only manufacturer of. that product, so the
use of the generic name or the
trademarked name becomes immaterial, e.g., Darvon (propoxyphene
HCl, Eli Lilly & Co.) and there
can be no controversy over equivalency. On the other hand, if many
companies manufacture the same
drug, in similar dosage form, the
question arises as to whether all
these products are equivalent with
respect to physiological and pharmacological potency.

Equivalency of Generic Products
This is important because in
many instances the prescriber has
a choice of designating a product
by its generic name or by a trademarked name. If the generic name
is used, the pharmacist is permitted to dispense that drug manufactured by any company. In this
method of prescribing the assumption is that all products of a specific
generic name are equivalent. With
our present knowledge, however,
there is doubt whether products
bearing the same generic name are
equally efficacious, e.g., sulfisoxazole (F-D-C Reports, Jan. 2,
1967) . It may be that the patient
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will get less than the desired dose,
because the product does not meet
labeled claim, or that the drug cannot be absorbed for some reason,
e.g., the tablet fails to disintegrate
or dissolve. If generic products are
not equivalent, then prescribing,
either voluntary or by directive,
becomes a question of good professional practice. Forcing a prescriber to prescribe any drug in
which he does not have confidence
or with which he has no experience, is a potentially dangerous
practice.
The problem of drug designation
is further complicated in that any
manufacturer can obtain a trademark for his products, and since
all drugs now have generic names,
both terms lose their power to differentiate between the quality of
drugs. There is a new term coming
into use, "branded-generics," which
nicely bridges the gap between
generic and trademarked drugs.
Trademarks are now being obtained for both old and new generic drugs. Comparing statistics between these two groups of drugs
becomes a meaningless game of
numbers.
In addition, the trademark is
on the drug, and not on the final
product (dosage form). Yet, the
patient is not given micro-packets
of powder or liquid to take; he receives a combination of ingredients, including the drug(s), which
makes an acceptable physical entity
that can be conveniently handled,
taken, or administered.

Discrepancies in Drug Costs

The cost of medication is interwoven into this controversy. The
products sold under generic names
are often less expensive than the
trademarked products, e.g., 5 mg
dextroamphetamine sulfate tablets
may be purchased for as little as
$1.25 for a bottle of 1,000 tablets,
or purchased as Dexedrine (Smith,
Kline & French Laboratories) for
$22.60 (Drug Topics Red Book
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1967). This phenomenon of price
differentials occurs in other fields
also.
The cost of medication is confounded by the pricing structure
of many pharmaceutical manufacturers. They sell their trademarked
products to government agencies
and hospitals at much lower prices
than to the community pharmacist.
It was reported that Upjohn Co.
sold prednisone tablets (5 mg) to
the Government at $4.94 per 1000
(F-D-C Rept., July 29, 1967),
whereas the price to community
pharmacists was $20.94 (Drug
Topics Red Book 1967). It was also
reported that Ciba would give a
bottle of 1,000 tablets free with the
purchase of two bottles of 1,000
tablets of Esidrex (hydrochlorothiazide) and Esidrex K (hydrochlorothiazide and potassium chloride). This offer was made to public
and private hospitals, dispensing
physicians, but not to pharmacists
(Weekly Pharmacy Rept., Jan. 2,
1967). Price cannot be equated to
quality. If it is, one may ask if the
manufacturers are making products
of two different qualities, an expensive one of higher quality and
a less expensive one of lower quality. Recently, E. R. Squibb & Sons
announced the new price for its
Sumycin (tetracycline). The product now will sell for $4.25 per
100 capsules (F-D-C Rept., August
14, 1967). This makes Squibb's
prices more competitive with generic products.
Many of the arguments given
against the concept of generic
equivalency arose before the 1962
Kefauver hearings. These hearings
resulted in the Drug Amendments
of 1962 to the Federal Food, Drug
and Cosmetic Act. These amendments gave new regulatory powers
to the FDA , and as a result many of
the problems associated with generic drugs due to poor manufacturing practices are being reduced or
eliminated. For example, the number of drug recalls have been inceasing every year (F-D-C Rept.,
Dec. 5, 1966) , indicating that the

poorer quality products are being
forced off the market.
There are those who would like
to see products prescribed by generic name only, and those who oppose this concept. The former
group assumes generic and product
equivalency; the latter group does
not agree that products are equivalent. Unfortunately, proponents of
both sides of the question of generic equivalency have indulged in
the luxury of stating half truths.
Let us take a close look at the
major arguments presented by the
opposing sides in the generic equivalency controversy.
For Generic Equivalency

1. All generic products are
equivalent, because they must meet
USP or NF standards. If they are
equivalent, then one can buy the
least expensive product.
Reply: These compendia set
standards for purity and identification of drugs and pharmaceutical
adjuvants and for the range of
drug content in various dosage
forms. The compendia do not guarantee therapeutic efficacy or give
formulas and directions for manufacture of dosage forms sold. Some
of the tests have limited value, e.g.,
the tablet disintegration test may
not be a reliable index of drug
availability from the tablet. In
some cases, the assay may be misleading, e.g., assay for total iodine
in Thyroid USP (Brune et al., 1962;
Gatz, Ginsburg, and Salenger,
1962; MacGregor, 1961; Williams,
Meister, and Florsheim, 1963).
Yet the standards prescribed by
these compendia generally reflect
present day manufacturing practices, because the committees which
establish the standards include industrial scientists.
2. The Defense Personnel Support Center buys only generic products. If these products are used
in the Bethesda hospitals and given
to our Presidents, generals, and
Congressmen, etc., why are they
not good enough for everybody?
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Reply: The Defense Department
buys its drugs under generic names
based on competitive bidding. Since
all drugs have generic names, and
anyone can make generic drug
products not covered by unexpired
patents, the bidding is open to all.
The Defense Department inspects
the manufacturing facilities before
accepting any bid. After the product is made, representatives from
the department again come to the
manufacturer to observe all the
final tests performed on the product. By this procedure the Defense
Department presumably receives a
product that meets all its specifications. Not even a large hospital,
let alone individual pharmacists,
can make these inspections. The
manufacturer of trademarked products competes under this system and
when successful, sells his trademarked product under its generic
name.
As the FDA increases the number
of inspectors and is able to enforce
its regulations more widely, drug
products should be of higher quality, because more manufacturers
will be operating under good manufacturing practices and with sufficient quality control.

Against Generic Equivalency
1. The large manufacturers of
trademarked products are engaged
in research to improve existing
drugs and to discover new drugs.
The prices of their drug products
must be higher to support this research. The small manufacturers
of generic products do not engage
in research, and have never discovered a new drug.
Reply: The companies who undertake research, do not do it for
altruistic reasons. They do it to
gain competitive advantages and to
make money. This is not to be condemned, but do not ask for public
support for it. Many other industries do research and support research, e.g., chemical, electrical,
petroleum, etc., but they ,do not

ask for public sympathy. The pharmaceutical industry's research efforts do not justify the large price
differentials that often exist many
years after the product has been
introduced, even if the successful
products must pay for the failures.
Companies that discover a new,
unique, and useful medicinal can
obtain a patent which runs for 17
years after the date of issue (about
three years after application). During this time they have a monopoly
on this drug, and there is no competition, generic or otherwise. In
this manner they can protect their
investment and make a profit.
2. The large manufacturers of
trademarked products have better
quality control and can spend more
time and money in the pursuit of
excellence. Their products are
purer and there is less likelihood
of contamination.
Reply: This should be true, but
they are not immune to mistakes
and accidental contamination. This
difference is slowly being reduced
by increasing FDA inspections, and
hopefully, this difference will continue to diminish. Mr. Hansen,
program operations director of the
Bureau of Regulatory Compliance
FDA, stated that there were less
than 70 recalls per year before
1962; there were 110 in 1964, 340
in 1965, and 449 in 1966. Of the
449 violations in 1966, 351 (78%)
were due to violations of the good
manufacturing practice regulations
(F-D-C Rept., Dec. 5, 1966).
Purity and control of contamination is a problem that has plagued
all manufacturers. Contamination
due to diethylstilbesterol (Weber
et al., 1963), estrogen (Hertz,
1958), selenium (Keller, 1960),
penicillin, Salmonella, metal particles in opthalmic ointments, etc.,
have occured in products of both
large and small manufacturers.
They are more likely to occur due
to poor manufacturing practices. In
1953, a study of vitamin preparations in Canada showed that subpotent products were produced
more often under conditions of

inadequate quality control than
those manufactured under adequate control (Campbell, 1953).
3. The trademark is the identification of the manufacturer, and
says he assumes responsibility for
the product.
Reply: True! Many manufacturers are concerned about their
"good name," and, therefore, may
exercise better quality control. All
manufacturers are responsible for
their products whether they have
a trademark or not. A trademark,
however, is not synonymous with
quality; anyone can obtain trademarks for his products.
4. Physicians, dentists, etc., prescribe by trademark because they
are familiar with the company and
its products and know the therapeutic results to expect from these
products.
Reply: True! But, do they really
know the company? How much of
the prescriber's information comes
from the company representative,
and how complete is that information? Ciba was accused of not
reporting toxicity data on Elipten
(amine-glutethimide) (FDA Rept.,
1966). Frosst made an inadvertent
mistake in its reformulation of
Dicumerol (bishydroxycoumarin)
(Lozinski, 1960) . Cannot the
physician just as well become acquainted with certain companies
that manufacture nonproprietary
pharmaceuticals?
5. Some formula ingredients in
a dosage form make generic prescribing hazardous for patients with
certain diseases that require restricted caloric or sodium intake.
When the physician prescribes by
trademark, he knows what the patient will be getting.
Reply: How does the physician
know what .the ingredients other
than the drug are? This information is not always readily available
to the prescriber. The manufacturers do not list tablet formula ingredients and their amounts. One
gram of sugar produces about four
calories and no tablet would contain this much sugar as a diluent.
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The prescriber must write to the
company to ascertain the ingredients.
It is possible that a large manufacturer may be more concerned
as to the ultimate user of his product, and therefore make adjustments in his formulation, e.g., omit
calorie producing materials or
sources of sodium ion. He would
state this in the package inserts,
etc.
6. When a generic product is
prescribed, the same product is
not always dispensed. This can lead
to varying therapeutic results. A
trademark or designation of the
manufacturer insures that the same
product is always dispensed.
Reply: The same product should
always be dispensed unless it is no
longer available. The source of the
generic product should be noted
on the prescription order by the
pharmacist, to insure that the same
product is dispensed when the prescription order is refilled.
When a patient is on long term
drug therapy, e.g., insulin, penicillin, anticoagulants, thyroid, etc., a
constant drug blood level in the
therapeutic range is necessary to
prevent relapse. A reliable product
which will give the same absorption pattern is necessary. Changing
brands may result in different levels
of the drug in the blood. The second brand may be satisfactory for
a patient just starting on the therapy regimen, but may not be satisfactory for refilling of a prescription order. Dosage adjustment is
easiest when the patient is just
starting therapy. The prescriber
learns what to expect from each
product regardless of the name.
7. The pharmacist has greater
liability when filling prescriptions
for products prescribed generically.
Reply: True, but what does this
have to do with the proper treatment of patients?
If a trademarked product is prescribed, or the manufacturer of the
product is stated on the prescription order, then the pharmacist has
no choice as to what to dispense,
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and he is only liable under the implied warranty doctrine. If a generic product is requested and the
manufacturer not designated, then
the pharmacist has a choice. If he
uses care and exercises his knowledge and experience to choose a
reliable product from a source in
which he has confidence, then he
cannot be considered negligent, but
the implied warranty doctrine still
applies. Since the product is sold
in interstate commerce, a new drug
application has been approved by
the FDA, so that the pharmacist
does not have to guarantee efficacy.
When products are prescribed by
generic name, the pharmacist has
more responsibility and hence
more liability, but he should be
willing to accept this.
8. Products sold under non-proprietary names do not maintain
their potency as well as proprietary
products.
Reply: This is one of the quickest tests that can be performed on
a product by the FDA or a state
agency. Judging from the results
reported in the Medical Letter
(Aug. 19, 1960), potency is rarely
outside the set limits. On the other
hand, taking the data collected by
the analyst of the city of Birmingham, England, it appears that the
potency of many English products
does not meet official requirements
(Bagnall and Stock, 1955). There
is not sufficient published data
available at this time to determine
if this statement is true.
9. The large manufacturer has
more staff, facilities, information,
and manufacturing "know how"
than the small company. Therefore
the large manufacturer is better
able to produce a more stable,
uniform, and efficacious product.
Reply: The large manufacturers
do not have a monopoly on information and the small manufacturer can hire knowledgeable and
experienced personnel. The good
manufacturing practice regulations
and their interpretation are available to all. A great deal of stability
data and incompatibility informa-

tion has been published. Unfortunately, however, the availability of
this information does not guarantee
its application. The FDA has this
knowledge too, and uses it in judging new drug applications, and in
their plant inspections.
The argument does not end here.
It has been demonstrated many
times that there are numerous factors in the formulation and manufacture of dosage forms that may
affect the efficacy of the product.
Levy and Nelson (1961) and Delgado and Cosgrove ( 1963) review
this problem in detail. These authors discuss the effect of variables
such as drug particle size, sterility
of ophthalmic preparations, rubber
and polymer closures on multidose
vials, ingredients of ointment and
suppository bases, salts and esters
of the parent drug molecules, and
the ingredients added to the drug
to permit manufacture of the dosage form such as solvent, sufactant,
and fillers.
A commonly used filler for tablets and capsules, dicalcium phosphate, was found to depress blood
concentration of tetracycline (Boger, 1959) . Drug particle size may
affect absorption of both oral and
parenteral product (Levy, 1963a),
e.g., sulfa drugs, griseofulvin, and
insulin. Increasing the solubility of
the tablet base increased the absorption of spironolactone (Levy,
1962). "Sgft" tablets of phenylindanedione produced drug blood
levels similar to that produced by
loose powder in capsules, whereas
"hard" tablets gave delayed and
poor absorption (Schulert and
Weiner, 1954). The salt form of
PAS and the presence or absence
of an enteric coating influenced
the PAS blood level (Frostad ,
1961). The salt form, molecular
modification, and the formulation
of aspirin tablets affected the salicylate blood level (Leonards, 1963 ;
Levy and Gagliardi, 1963; Levy
and Sahli, 1962). An in vitro test
to determine the dissolution rate
of a drug has explained why certain drug products, such as predni-
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sone (Campagna et al., 1963) and
tolbutamide (Levy, 1963b), were
reportedly poorly absorbed. In an
investigation of 18 commerically
available tolbutamide tablets, it
was found that the amount of drug
dissolved at the end of one hour
varied from 30% to 86% (Brudney, Stewart, and Eustace, 1963).
In vitro studies (Levy et al., 1963;
Levy and Gumtow, 1963) have
shown several factors that influence the rate of tablet dissolution.
Studies have shown that in commerically available sustained release products, drug absorption
may vary from complete absorption immediately (no sustained effect) to almost no absorption
(Shenoy, Chapman, and Campbell,
1959).
Stability of a product is important not only because the potency
of the product must be maintained,
but also because the decomposition
products may produce untoward
reactions, e.g., tetracycline (Frimpter et al., 1963; Editorial, J. Am.
Med. Assoc. , 1963).
Isolated clinical cases have been
reported in which a generic product gave poorer results than a
trademarked product, e.g., prednisone (Keller, 1960), cortisone
(Rosenheim and Ross, 1958, Boch,
19 59; Bayliss, 19 59), tolbutamide
(Carter, 1963; Caminetsky, 1963),
and phenylbutazone (Searl and
Pernarowski, 1967) . Even if ineffectiveness has not been shown,
it may still be there.
We have learned much about the
formulation and manufacture of
dosage forms, often only after the
product has been marketed. Oversights, even by large manufacturers, have come to light in this manner. The large manufacturer has
the personnel and the facilities that
would seem to make him more
able to do thorough investigations
before marketing a product, but
he has not always done so.
The large companies also have
produced drugs for a very limited
market as a public service, because
the drug is needed. This is not an

argument against generic equivalency.
Conclusion
The truth about generic equivalency has not yet been determined.
The arguments in the generic equivalency controversy are confounded
by names, proprietary (trademark,
brand name) as opposed to nonproprietary (generic, branded-generic), yet quality of the products
is not necessarily related to any
name. The efficacy and not the
name of the product is important.
The crucial question to ask is
whether the product is clinically
or therapeutically effective, giving
reliable and uniform results.
Drugs called by their generic
names are here to stay and more
than likely their use will increase,
especially as state and federal
governments pay more of the medication bills. Kentucky and Louisiana already have issued lists of
generic equivalents to trademarked
products.
Meanwhile, the prescriber and
the pharmacist still must ponder
the question of therapeutic equivaIency of drug products. What product is to be requested on a prescription order and what product
is to be dispensed if the drug is
prescribed by its generic name.
More information is needed to answer this question. Clinical trials
testing the hypothesis of generic
equivalency are required. A national clearing house for information on the efficacy of drug products may be necessary. A national
organization such as the American
Pharmaceutical Association, American Medical Association, or the
FDA, or an organization composed
of representatives of interested
groups could collect and disseminate the information to physicians,
dentists, pharmacists, etc.
The U.S. Pharmacopeia and National Formulary monographs
should include formulas and manufacturing directions for the various
drug products. The specifications
should be based on clinicaI!y dem-

onstrated efficacy. The monographs
could also include information on
known factors that may impair
the effectiveness of the product.
Formula and process variations
would be permitted only if the
same therapeutic results can be
demonstrated clinically.
The knowledge that the Defense
Department has concerning its
drug purchases and the use of these
products in its facilities could be
made available. Manufacturers,
both large and small, could make
available clinical and physiochemical data on their products, such
as assay, drug content variation per
unit dose, tablet dissolution rates,
drug levels in blood or urine, and
stability. It is important that the
FDA or the proper state agency be
informed of any suspected drug
products so that substandard products may be removed from the
market as rapidly as possible.
Finally, it is necessary that more
people become aware of the true
magnitude of the problem of generic equivalency. Because of the
present Jack of knowledge of which
drug products are therapeutically
equivalent, the prescriber and pharmacist must rely on their experience as to which products and
companies are reliable. They must
also continually search their journals for information on the therapeutic equivalency of products.
Perhaps the pharmacist should compile information on generic and
therapeutically equivalent drug
products, which companies consistently make poor products, using
sources as Weekly Pharmacy Reports (The Green Sheet), F-D-C
Reports (The Pink Sheet), FDA
Papers (U.S. Government Printing
Office), and The Medical Letter on
Drugs and Therapeutics. These
compilations would then be available for the prescriber.
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Perspectives and Prospects in the
Chemotherapy of Gastrointestinal
Cancer*
WILLIAM REGELSON

Department of Medicine, Medical College of Virginia,
Richmond

The goal governing dosage schedules for the chemotherapy of gastrointestinal cancer has been , in
general , to induce significant drug
toxicity in order to insure maximum therapeutic effect. The pursuit of maximum therapeutic effect
led logically to the development of
"Life Islands" which permit the isolated, relatively germ-free care of
patients treated with intensive chemotherapy. However, intensive chemotherapy may have deleterious effects on patients other than that of
increased susceptibility to infection.
It is, therefore, important to be
aware of the alternative approaches
implied in a recent analysis of data
obtained from the Eastern Clinical
Drug Evaluation Program ( CDE P) .
In this cooperative study, Bross et
al. (1966a, b, c) have shown that
patients manifesting drug toxicity
do not necessarily show a greater
frequency of tumor regression than
do patients without toxicity.
In the CDE P program a total of
956 patients were treated with 5fluorouracil ( 5-FU), dimethylurethamine (AB-132), mitomycin C,
chlorambucil , and 6-mercaptopurine (6-MP) in a 60-day study of
objective response. There was no
increase in tumor response with
high toxicity scores. In fact, the
patients with the greatest toxicity
showed a somewhat lower tumor
response. These data (Ausman,
1965; 1966 ; Bross, 1965; Bross et
* Supported by grant CY 2821 ,
U .S.P.H.S.
MCV QUARTERLY 3(2): 119-126, 1967

al., 1966a, b, c) suggest that overt
toxicity may not always be necessary to obtain an oncolytic effect.
This is further supported by a recent study of the Eastern Solid Tumor Group which compared 5-FU,
fluorodeoxyuridine (FUDR), and
methotrexate (MTX) at dose levels
producing comparable toxicity in
a group of patients with colon-rectal and breast cancer (Hall, in
press; Schneiderman and Krant,
1966). With increased toxicity a
plateau was reached beyond which
no significant further regression of
tumor could be obtained, and survival , despite tumor response, was
shortened in comparison to those
patients showing tumor response
but minimal drug toxicity (fig. 1) .
These observations as well as
those of Ansfield ( 1964) and others
(Cudmore and Groesbeck, 1964;
Groesbeck and Cudmore, 1963)
are supported by animal data
(Louis, 1965) and suggest that it
is not necessary to take patients to
toxic drug levels to achieve a significant remission. Such data should
reinforce our awareness of the possible deleterious effects of drug action on survival and remind us that
the gain afforded by tumor regression can be lost in the morbidity
and mortality induced by drugs.
The Eastern CDEP data suggest
that 5-FU and mitomycin C can
produce significant therapeutic effects without severe toxicity (Ausman, 1965; 1966; Bross, 1965;
Bross et al., 1966a, b, c). Therefore, it is important to avoid severe
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diarrhea, stomatitis, and marrow
depressions with white counts below 3,000/ mms or platelet counts
below 75,000/ mm 3 • When used this
way, 5-FU becomes of more general clinical usefulness in gastrointestinal cancer.
A renewed interest in alkylating
agents has resulted from observations indicating objective tumor regression ( > 50 % shrinkage) in
colon-rectal cancer with AB-132 (8
of 33), gastric cancer with AB-132
and chlorambucil ( 6 of 26), and
pancreatic cancer with AB-132 and
chlorambucil ( 6 of 8) in a study
by the Eastern CDEP (Ausman,
1965; 1966; Bross, 1965; Bross et
al., 1966a, b, c).
Chlorambucil showed no activity
in 15 patients with rectal cancer,
while 5of12 responded toAB-132.
Chlorambucil was given by mouth
and appeared to be most effective
in the upper gastrointestinal tract.
Unfortunately, this study as performed by the Eastern CDEP was
non-comparative and limited to
only two months of observation in
ambulatory patients. More critical
studies of these agents need to be
done. In the meantime, the ease
with which chlorambucil can be
given makes it worthy of serious
consideration as a useful agent in

gastric and pancreatic cancer, although its superiority to other alkylating agents has not been clearly
shown. Similarly, AB-132 or another parenteral alkylating agent
can be used in colon-rectal cancer.
Chemotherapy Combined
with Surgical Treatment
Laboratory evidence has supported the usefulness of adjuvant
prophylactic chemotherapy at the
time of surgery in the absence of
known disease. However, the clinical applications of this evidence
have shown puzzling results. There
is no improvement in recurrence
rates in men with colon-rectal cancer who received high-dose thioTEP A (0.8 mg/kg) at the time of
surgery, although women show a
significantly increased survival time
(U.C.L.A. Statistical Unit, 1965) .
In this study a high dose, with its
increased mortality and morbidity,
was felt necessary. Fluorodeoxyuridine (FUDR) used as an adjuvant
by the Veterans Administration
study shows no significant difference in recurrence rate at 30
months (personal communication,
M. W. Wolcott, 1965). These
studies await simultaneous controls
but evidence supports the possibility
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Fig. 1-Colon and rectum cancer. Eastern group double blind, 3 drug study (all
drugs combined). Data and graph courtesy of M.A. Schneiderman, M. J. Krant,
and T. C. Hall of the Eastern Solid Tumor Group. A major portion of this data
was presented in Cancer Chemotherapy Rept. 50: 107-112, 1966.
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that repeated 5-FU administration
increases the survival of patients
with occult tumor left behind.
Recently, Mackman and Curreri
( 1967) reported the results of a
"second-look procedure" evaluating
patients who had curative resections
for colon cancer but who showed
positive mesenteric node or serosal
involvement at the time of "curative" resection. Post-operatively,
these patients were given 5-fluorouracil for four or more courses
prior to their "second-look," one
year post operatively. Twenty patients were examined, 17 of which
had no tumor at the end of this oneyear period. An additional 11 patients who had direct extension to
adjacent organs or structures, who
were treated with only palliative
resection, were examined following
four to 10 courses of 5-fluorouracil.
Seven of these patients were free of
tumor, and three had tumor which
was removed for possible "cure."
This experience has recently been
supported by a report by Rousselot
et al. (1967, in press) who have reported on the survival of patients
over a five-year period following
the effectiveness of both intraluminal 5-fluorouracil administration
and systemic intravenous 5-fluorouracil in the post-ope.rative period.
This was a comparative study between nitrogen mustard and 5-fluorouracil. Adjuvant nitrogen mustard
had no effect on statistics regarding
recurrence rate. However, for 5fluorouracil in those patients who
had nodes (stage 3) significant improvement appeared. At five years
the survival rates were 65 % for
the 5-fluorouracil treated versus
32% in a nationwide control series
and 26 % in the St. Vincent's Hospital control series. There was no
apparent imorovement in survival
rates in st:ige 1 and 2 colon cancer
cases (negative nodes) as compared
to those seen on the basis of the
nationwide avernges and this reflects the over all effectiveness of
surgery in earlv colon cancer.
These studies despite the lack of
concomitant controls point out the

possible usefulness of an adjuvant
drug in the treatment of colon carcinoma particularly when known
tumor is left behind.
The value of massive intermittent
chemotherapy in the absence of
clinical disease as applied to acute
leukemia is a proven one (Hananian, Holland, and Sheehe, 1965),
but proof of an analogous situation
in colon-rectal cancer is only suggestive and requires further data.
A study of this kind for gastric and
bowel cancer using repeated courses
of cytoxan or mitomycin C is being
conducted in Europe (Karrer,
I 964a and b), and the results
should be of great interest when
they become available.
Wood et al. ( 1961) and others
(Cliffton and Agostino, 1963;
Koike, 1964) found a decrease in
the viability of circulating tumor
cells following the administration of
fibrinolysins or anticoagulants. The
adjuvant anti-tumor action of anticoagulants has not been explored
at the clinical level, but there are
controversial retrospective epidemiological data that suggest that cancer patients who received anticoagulants for post-surgical phlebitis
or coronary disease may have
shown an increase in tumor-free
survival time (Michaels, 1964) .
Based on this evidence, a study using heparin or fibrinolysin in the
postoperative period deserves serious consideration.
Regional perfusion has limited
value except in very special cases
(e.g., primary or metastatic disease
to liver) and may not offer more
palliation than is produced by systemic drug administration. However, the aggressive approach of
repeated intra-arterial administration of cytoxan and 5-FU by Bierman's group (Mesler, Winer, and
Bierman, 1965) deserves closer attention as does the work of Sullivan et al. (196'i) on prolonged
intra-arterial infusions.
The frequency of cancer cell
seeding in abdominal wounds has
led to the development of animal
screening methods to develop ef-

fective agents for wound irrigation
that would kill tumor cells. The
clinical use of monoxychlorosene
(Chlorpactin XCB) and mechlorethamine (HN,) and Thiotepa
(TSPA) followed on these observations. Despite the demonstrated
optimal activity of Na Hypochlorite and HN, as tumorcidal agents
in an animal tumor implantation
screen, long-term follow-up of head
and neck cancer patients receiving
post-operative wound irrigation with
these agents has shown accelerated
tumor take in the irrigated area
when compared to wound washing
with normal saline (Mukhtar et al.,
1963). More recent five-year survival data fully supports these observations. These studies indicate
that so called "topical chemotherapy" or "cytocidal wound irrigation" and should be absolutely contraindicated in the treatment of
gastrointestinal cancer until long
term follow-up indicates the efficacy of newer agents.
Radiotherapy Adjuvant
Chemotherapy

Radiotherapy in combination
with chemotherapy for synergistic
or additive effect has a valid rationale, based on data of responsive
animal tumors, when combined
with AB-132 (Regelson and Pierucci, 1964), 5-FU (Heidelberger
and Ansfield, 1963; Baclesse, Duplan, and Romer, 1964), or mitomycin C (Baclesse et al., 1964).
Results from past clinical studies
of this type are difficult to analyze
owing to the absence of concomitant controls. Jn addition, such large
doses of both drugs and radiation
were used that the therapeutic gain
possible through a more judicious
selection of dosage levels may have
been lost. One cannot expect patients with advanced cancer to
show increased survival time when
treated with comhinations of radiation or drugs that would result in
severe debilitation from either
agent alone. Despite these difficulties there are reports of increased
survival for patients with cancer of
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the pancreas or stomach treated
with 5-FU in conjunction with
radiation (Moertel et al., 1965).
The current Veterans Administration long-term continued study
which uses combinations of FUDR
with radiation may give a more
definitive answer, but systemic or
local effects on host resistance
could nullify the anti-tumor effect.
New Approaches to
Chemotherapy

Of particular interest are drug
combinations which may act synergistically or additively by interfering with alternative metabolic
pathways to eliminate the resistant
tumor population. Most of the studies reported so far are preliminary
and have not unequivocally demonstrated the virtues of combination chemotherapy in gastrointestinal cancer over the action of single
agents. A report of regression in a
pancreatic and epidermoid cancer
with the combination of 6-thioguanine with duazomycin A is encouraging and is based on sound rationale (Lefkowitz et al. , 1965) .
Animal data in the area of collateral sensitivity has not been systematically applied to human tumors. The results of one collateral
sensitivity study that could be applied immediately demonstrated that
a 5-FU resistant tumor in rodents
showed increased response to alkylating agents (Rutman, 1964). To
my knowledge this observation,
which calls for the use of an alkylating agent after failure to respond
to 5-FU, has not been tested
clinically. Similarly, there are
laboratory observations that uracil
mustard makes transplanted Sarcoma-180 tumor cells in mice more
sensitive to the anti-tumor action
of 6-thioguanine (Booth, Creasey,
and Sartorelli, 1964). Reports of
synergistic inhibition of S-180 by
mitomycin C and 6-thioguanine or
5-FU (Sartorelli and Booth, 1964)
are also clinically interesting, since
the clinical pharmacology of these
agents is well known.
A study is warranted on the use
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of methotrexate in 5-FU resistant
patients based on the hypothesis
that the resistant tumor may be dependent on a de novo pathway of
thymidylate synthesis (Welch,
1963). However, Weiss and Jackson (1961) gave patients with gastrointestinal tract cancer MTX ( 5
mg orally per day) following 5-FU
and found no evident therapeutic
gain. More recently evidence has
accrued that MTX can increase the
level of thymidylate synthetase in
human leukemia (Roberts, 1966) .
Thus pretreatment with MTX may
deleteriously effect the response of
tumor cells to 5-FU.
Suitable for more immediate
study is the verification of suggested
evidence in man that glucose enhances 5-FU therapeutic effect
(Gotto, Belkhode, and Touster,
1964; Kessel , 1966; Lemon et al. ,
1963). lnosine (Gotto et al., 1964)
or adenosine (Kessel, 1966) also
results in increased tumor-cell uptake of 5-FU. These observations
may have clinical bearing and
should be tested in comparative
studies.
The importance of varied dosage
regimens is seen in the observations
that the prolonged intravenous administration of 5-FU is less toxic
than rapid drug administration .
However, any therapeutic gains
from prolonged infusion may be
offset by the convenience of rapid
intravenous injection and greater
control of dosage. Moertel et al.
(1964) have found no improvement in therapeutic results with
5-FU in prolonged intravenous administration as opposed to the
single rapid daily loading program.
Similar anti-tumor results, but with
considerable decrease in toxicity,
have now been observed clinically
by Ansfield (1964) using 12 mg/
kg/ day for four days as compared
to the earlier program of 15 mg/
kg/ day for four days, and the lower
dose should clearly be the one of
choice. Furthermore, the selection
of patients for treatment with 5-FU
should exclude severely debilitated
patients, since such patients show a
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decreased drug tolerance. This is
supported by data in the nutritionally deprived rat (Wolberg and
Curreri, 1960). In using 5-FU, it
is well to remember that reports of
a high order of regression such as
that of Vaitkevicius et al. ( 1961) ,
objective regression in 20 of 55 patients with adenocarcinoma of the
large bowel, are tempered by the
observation that regression was
clinically worthwhile in a small proportion and even that occurred at
the expense of severe toxicity in
many patients. However, as discussed earlier, the evidence that responses can be seen in the absence
of discomforting clinical toxicity or
serious hematopoietic depression indicates that 5-FU might be given
to advanced cancer patients for
shorter periods and at lower dosage
to avoid toxicity. In such a study
Young et al. (1960) obtained responses in 10 % to 15 % of patients with bowel cancer with total
dosage ranging from 30 to 150 mg/
kg. Similar results have been obtained by Ansfield ( 1964) and others (Cudmore and Groesbeck,
1964).
The topical administration of
5-FU in a 10 % ointment base has
resulted in the disappearance of
metastatic cutaneous adenocarcinoma of the bowel without damage
to normal skin (Klein et al. 1965).
This observation, while limited in
its application, is pertinent to a consideration of using local 5-FU for
palliation of recurrent or residual
tumor. Up to 10 % of 5-FU is adsorbed by the gastrointestinal lining
of the tumor segment (Cole, 1963) .
Patients have tolerated up to 8 mg/
kg/day P .O. for up to six weeks
with gastrointestinal side effects occurring, on an average, in 18 days
and hematologic toxicity in 21 days
(Ellison, 1962). Although anti-tumor effects have been seen (Cole,
1963; Ellison, 1962; Kennedy and
Theologides, 1961; Khung, 1965) ,
the virtues of local intraluminal
instillation of 5-FU into tumorinvolved segments of bowel in
prophylactic or adjuvant studies

have not been adequately explored.
There are other agents becoming
available, and reports of new drugs
are awaited with interest. For example, antibiotics which behave
similarly to actinomycin D, such
as chromomycin A., olivomycin,
and mithramycin, which combine
with DNA to impede RNA synthesis (Ward, Reich, and Goldberg,
1965) may show promise (Mayevsky, 1964; Akopliants, 1962). Studies of ethidium and daunomycin
which have effects in common on
purine metabolism (Ward et al.,
1965) may prove useful. 6-Azauridine has been reported to produce
objective improvement in one of
three gastric and pancreatic carcinoma patients for periods of four
to five months (Welch et al., 1960).
There is fairly extensive Japanese literature regarding the clinical efficacy of a variety of porphyrin derivatives (Fukuyama, Tsuji,
and Nakagawara, 1963; Matsubara et al., 1963; Tazaki, 1962;
Tazaki and Fume, 1961). Hematoporphyrin mercury was reported
to inhibit nucleic acid metabolism
in stomach and intestine with an
increased uptake of the drug in tumor as compared with normal tissue. This compound was said to
produce objective and subjective
improvement in several patients
with gastrointestinal cancer (Fukuyama et al., 1963; Tazake, 1962;
Tazaki and Fume, 1961 ) . Similar
effectiveness was reported for a cob alt protoporphyrin preparation
(Fukuyama et al., 1963; Matsubara
et al., 1963). It is hoped that an
evaluation of these reports will not
take as long as those studies involving mitomycin C.
In early clinical trials the toxicity
which eventually blunts the initi al
enthusiasm of extended trial is frequently minimized. It was this type
of experience with mitomycin C
that delayed its entry into clinical
practice. Much of the Japanese
work with mitomycin C has been
associated with its administration as
an adjuvant at the time of surgery
(Frank and Osterberg, 1960; Os-

ada, 1963; Shiba, 1963). A threeyear survival rate of 66 % in comparison with a control of 30 % was
found by Osada et al. ( 1963) in
patients with gastric cancer who
had undergone palliative surgical resection. Skepticism is in order, since
one can also find reports indicating
increased survival time in patients
treated after gastrectomy with
mechlorethamine, nitromin, sarkomycin, or carzinophilin (lshiyama,
1965), P32 and TSPA (Osada,
1963). Hoerr ( 1965) has found an
11 % five-year survival rate in palliative surgical resection for gastric
cancer even in the absence of chemotherapy. Similar results have been
obtained in untreated bile duct tumors (Lippman, McDonald, and
Longmire, 1959). Therefore, isolated case reports of long term responses must be analyzed carefully,
as they may be related to the selection of a group of long-term survivors that are present in any given
gastrointestinal tumor population.
Varied approaches to dosage and
timing of drug administration are
important in any program of drug
evaluation. This was dramatically
demonstrated when the "old" drug,
methotrexate, was used in a new
way which led to the cure of choriocarcinoma (Li, Hertz, and Spencer, 1956) . Modified methotrexate
regimens increased survival of children with acute leukemia (Selawry
and James, 1965; Acute Leukemia
Group B, 1965) and are producing
responses in bronchogenic carcinoma (Ross and Selawry, 1965)
and bowel cancer (Condit, Shnider,
and Owens, 1962). The twice-aweek administration of methotrexate (0.25 mg/kg or 0.6 mg/kg) for
gastrointestinal cancer is under
study by the Eastern Solid Tumor
Group, and the results are awaited
with interest.
As suggested by this review,
much remains to be done in the
chemotherapeutic approach to gastrointestinal cancer. The conservative use of 5-FU and alkylating
agents have a place provided that
severe toxicity is avoided. The sur123
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gical adjuvant use of 5-FU has a
rational basis and its application to
patients with nodal involvement or
disease left behind is warranted. It
is hoped that studies will continue
that can lead to comparative information pertinent to evidence of objective regression of disease and
the practical reality of increased
survival.
Summary
5-Fluorouracil (5-FU) is the best
agent for the treatment of a ll gastrointestinal cancers but should be
used with restraint, since severe
toxicity does not guarantee increased response or survival time.
Experimental work suggests that
glucose enhances cellular upta ke of
5-FU. Alkyl ating agents are definitely useful and occasionally produce long-term responses. Mitomycin C shows activity but is not
available. There are reports of responses to methotrexate, vinca alkaloids, and mithramycin, but their
place in the m an agement of gastrointestinal cancer is not established .
The usefulness of alkyl ating agents
or 5-FU as adjuvants to surgery is
not clear, but evidence is accumulating which supports the adjuvant
use of 5-FU when disease is left
behind. There is laboratory evidence that anticoagulation ca n prevent tumor recurrence, and this
should be studied further. The best
combination chemotherapy has not
been determined. Regional chemotherapy offers a logical approach,
but comparative data with systemic
treatment are lacking, although
techniques for protracted infusion,
particularly of primary a nd secondary hepatic tumors, m ay justify its
increased use. Wound washing with
available contact tumoricidal agents
is contraindicated, as it may increase local recurrence.
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CORRECTION: Vol. 3, No. 1
(Spring), 1967, p. 36. In table 1,
a number of stage I patients included in the period from 1955 to
1960 were treated surgically (with
or without additional irradiation) ~
most, however, were irradiated
only. Stage II through IV patients
received irradiation only.

BOOK REVIEW

The Traveler's Health Guide. B. H.
Kean and Harold A. Tucker.
Springfield, Illinois: Charles C
Thomas, 1965. 217 p. $4.95.
The increase in foreign travel
has produced an admirable interest
in international health. Drs. Kean
and Tucker's preface states that
"This book has been written for the
international traveler, with best
wishes for his continuing good
health." It contains information
useful to the physician not only as
a traveler, but also as a practitioner
who must answer the queries of his
medically sophisticated patients.
The section on the universal "Diarrhea of Travelers," otherwise
known as "turista, Aztec two-step,
Casablanca crud, the Lower Burmas, the G.I.'s, and to demonstrate its universality, San Franciscitis", is a summary of a series
of investigations by Dr. Kean who
is professor of clinical medicine
(tropical medicine) at Cornell University Medical College. His recommendation of diphenoxylate hydrochloride (Lomotil) as a control
measure was justified recently in
this reviewer's experience. About
one-quarter of the book's contents
justifiably pertain to the prevention
and treatment of the communicable
disease, but other health aspects of
travel such as motion sickness and
allergies receive attention in one or
the other of the volume's three
sections entitled "Preparations for
Staying Well Abroad," "Traveling
or Living Abroad," and "And Now
You Are Home. . . ."
The final 34 pages of the book
consist of three appendices which,
apart from the first two pages
which list 17 references, could

have been omitted. One reference
not noted is the Consumers Union
publication, Health Guide for
Travelers, a 41-page pocket-sized
50¢ pamphlet which contains an
adequate amount of information
for the layman. A further reduction in size, and presumably therefore in price, could have been
achieved by eliminating items such
as "Packing," "Tipping," "Soft
Pricing," "Allowances, Duty-free
Gifts, Restricted Articles," "The
Advantages of a Travel Agent,"
and "Passports and Visas" in Chapter IX which purports to be "A
Few General Hints for Your Consideration." Appendix II, "Visa Fee
Schedule," which states that "Information of this nature is subject to
change . . . persons . . . should
check the passport and visa requirements with the consular official" then spends 18 pages supplying this information. Appendix
III deals with "Frostbite," a somewhat unusual concomitant of modern travel which hardly warrants a
discourse of 14 pages. All in all,
however, the authors have improved upon previous publications
in this genre and have written a
valuable text for international travelers and their medical counselors.
Note : Since this review was written
a companion volume has been published specifically for physiciansTraveler's Medical Guide for Physicians. B. H. Kean and Harold A.
Tucker. Springfield, Illinois: Charles
C Thomas, 1966, $12.50.
F. J. Spencer, M.B., B.S., M .P.H.
Professor and Chairman
D epartment of Preventive Medicine
Medical College of Virginia
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Leighton Cluff (Epidemiology of Adverse Drug Reactions) is chairman of the department of medicine at the University
of Florida. A graduate of the University of Utah, Dr. Cluff received his medical degree from George Washington University and took his clinical and research training at Duke University, the Johns Hopkins University, and the Rockefeller
Institute. Before moving to the University of Florida in 1966, Dr. Cluff was head of the division of allergy and infectious
diseases at Johns Hopkins, where he had been a member of the faculty since 1954.
George T. Harrell (The Physician as Humanist) took his medical degree and residency (in medicine) at Duke University. After teaching at Duke one year, he joined the faculty of the newly formed Bowman-Gray School of Medicine
of Wake Forest University, leaving there in 1954 to accept an appointment as dean of the University of Florida College of
Medicine, then being established. In 1964, Dr. Harrell moved to the Pennsylvania State University as director of the
Milton S. Hershey Medical Center and dean of the new school of medicine.

Werner Lowenthal (The Con/roversy Over Generic Equivalency of Drugs), a native of Germany, received his B.S. from
Albany College of Pharmacy and his M.S. and Ph.D. (in pharmaceutical chemistry) from the University of Michigan.
After completing his graduate training, Dr. Lowenthal was engaged in research for a pharmaceuticals manufacturer for
three years. He later joined the faculty of the MCV School of Pharmacy, where he is associate professor.
Nancy H. McGinnis (The Treatment of Anxiety) is research assistant in the department of psychiatry at the University
of Florida, Gainesville. She received her B.A. degree in psychology and mathematics from the University of Florida in
1962 and is now a candidate for the M.A. in psychology and statistics there. Her current research interest is in anxiety.
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Maurice McGregor (Pharmacology of Anti-Angina/ Agents) was born in South Africa and received his medical degree
from the University of the Witwatersrand, Johannesburg, in 1942. He joined the staff of McGill University in 1957, where
he is professor of medicine and research director of the cardiac division of the Joint Cardio-Respiratory Service of the
Royal Victoria Hospital and the Montreal Children's Hospital. On September 1, 1967, he was appointed Dean of the
Faculty of Medicine.
Robert H. Moser (Iatrogenic Disorders) received his medical degree from Georgetown University, where he also took a
residency in internal medicine. In addition, Colonel Moser has taken further training in cardiology (Brook Army Hospital), pulmonary disease (D.C. General Hospital), and hematology (Salt Lake County Hospital). Colonel Moser joined the
U. S. Army Medical Corps in 1948, and is now chief of the department of medicine at Brooke General Hospital,
San Antonio, Texas.

William Regelson (Perspectives and Prospects in the Chemotherapy of Gastrointestinal Cancer: A Critical Review) is
chairman of the division of medical oncology at the Medical College of Virginia. He received his A.B. degree at the University of North Carolina and his M.D. from the New York State University College of Medicine, Downstate. Dr.
Regelson's clinical and research training was at Maimonides Hospital, Memorial Center for Cancer and Allied Diseases,
and Roswell Park Memorial}nstitute. Before coming to Richmond he held staff appointments at Roswell Park and N. Y.
State University at Buffalo.
John J. Schwab (The Treatment of Anxiety), a native of Kentucky, received his medical training at the University of
Louisville. Al present he is associate professor of psychiatry and medicine at the University of Florida College of Medicine, Gainesville. He is certified in internal medicine and psychiatry and is an associate editor of Psychosomatics.
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Robert S. Schwartz (Some Perspectives on lmmunosuppressive Drugs) received his M.D. degree from New York University
in 1954. He is presently associate professor of medicine at Tufts University School of Medicine and chief of the clinical
immunology service of the New England Medical Center Hospitals.
Albert J. Wasserman (The Pharmacology of Newer Diuretics), professor of medicine and chief of the division of clinical
pharmacology at MCV, received a B.A. degree from the University of Virginia and an M.D. from MCV. He took his

hospital training at Beth Israel Hospital, Boston, and MCV, after which he joined the MCV faculty in 1957. From 1960
through 1963, Dr. Wasserman was chief of the medical service at McGuire Veterans Hospital in Richmond.
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when stress results in
muscle strain and pain
When the normally sedentary person suddenly turns
active-cleaning the attic, for instance-the outcome
is sometimes a strain or sprain in the back, neck or
shoulders.
Fortunately, however, most patients with muscle
spasm and pain are highly responsive to therapy
with Robaxisal. This rationally based formula provides the we11-known relaxant benefits of methocarbamol for strained, tense skeletal muscle plus the
dependable analgesic and anti-inflammatory effects
of aspirin. Investigators have found methocarbamol
a well-tolerated agent with "specificity of action." 1
And methocarbamol potentiates the salicylate levels
of aspirin so that, in combination;' higher salicylate
levels are produced than with equivalent doses of
aspirin alone. 2 When the Robaxisal combination*
was administered to a group of 22 patients with
painful musculoskeletal disorders, 20 (91 per cent)
showed an exce11ent or good response. 2
With Robaxisal you can conveniently fulfill the most
important objectives in treatment of muscle spasm:
relaxation of skeletal muscle, relief of pain, restoration of mobility and normal muscle tone. And when
mild anxiety is a factor in the spasm-pain syndrome,
consider Robaxisal®-PH.
•Jn thi s inves tigation, 400 mg. methocarbamol was combined with 300 mg. aspirin.
References: 1. Wei ss, M ., and Weiss, 5.: J. Am. O steopa th. A. 62:142, 1962. 2. Truitt,
E.B., Jr.; Morgan, A.M., and Nachman, H .M.: South. M.J. 54:318, 1961.

!!!JbaxisaI®brings
relief
fi ti th
Each pink and white laminated tablet contains:
Robaxin (methocarbamol, Robins) ............ 400 mg.
U.S. Pat. No. 2770649
Aspirin (5 gr.) ............................. 325 mg.

Robaxisal°-PH
Each green and white laminated tablet contains:
Robaxin (methocarbamol, Robins) ............ 400 mg.
Phenacetin .......... .... ....... . ............ 97 mg.
Aspirin .. ... ....... .. ................... , ... 81 mg.
Phenobarbital (1 /8 gr.) ...................... 8.1 mg.
(Warning: May be habit forming)
Hyoscyamine sulfate ...................... 0.016 mg.
ROBINS COMPANY, INC.
A·H·DtO
I\: BIN s A.H.
RICHMOND, VIRGINIA 23220
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Robaxisal and Robaxisal-PH are indicated when both analgesic and
skeletal muscle relaxant effects are required, as in strains and· sprains,
painful disorders of the back, "whiplash" injury, myositis, pain and
spasm associated with arthritis, torticollis, and headache associated
with muscular tension.
Contraindications: Hypersensitivity to any one of the components.
Side Effects: Lightheadedness, slight drowsiness, dizziness, and nausea
may occur rarely in patients with unusual sensitivity to drugs, but
usually disappear on reduction of dosage.

WHEN ANXIETY
IS A SIGNIFICANT
COMPONENT OF THE
CLINICAL PROFILE
LIBRIUM"
(chlordiazepoxide HCI)
Also available as
LIBRITABST.M. (chlordiazepoxide)
5-mg, 10-mg, 25-mg tablets

Before prescribing, please consult complete product information, a summary of which follows:
Contraindications: Patients with known hypersensitivity to the drug.

•

Warnings; Caution patients about possible combined effects with alcohol and other CNS depressants. As with all
CNS-acting drugs, caution patients against hazardous occupations requiring complete mental alertness (e.g.,
operating machinery, driving) . Though physical and psychological dependence have rarely been reported on
recommended doses, use caution in administering to addiction-prone individuals or those who might increase
dosage; withdrawal symptoms (including convulsions), following discontinuation of the drug and similar to
those seen with barbiturates, have been reported. Use of any drug in pregnancy, lactation, or in women of childbearing age requires that its potential benefits be weighed against its possible hazards.
Precautions: In the elderly and debilitated, and in children over six, limit to smallest effective dosage (initially
10 mg or less per day) to preclude ataxia or oversedation, increasing gradually as needed and tolerated. Not
recommended in children under six. Though generally not recommended, if combination therapy with other
psychotropics seems indicated, carefully consider individual pharmacologic effects, particularly in use of
potentiating drugs such as MAO inhibitors and phenothiazines. Observe usual precautions in presence of impaired renal or hepatic function . Paradoxical reactions (e.g., excitement, stimulation and acute rage) have been
reported in psychiatric patients and hyperactive aggressive children . Employ usual precautions in treatment of
anxiety states with evidence of impending depression; suicidal tendencies may be present and protective measures necessary. Variable effects on blood coagulation have been reported very rarely in patients receiving the
drug and oral anticoagulants; causal relationship has not been established clinically.
Adverse Reactions: Drowsiness, ataxia and confusion may occur, especially in the elderly and debilitated. These
are reversible in most instances by proper dosage adjustment, but are also occasionally observed at the lower
dosage ranges . In a few instances syncope has been reported . Also encountered are isolated instances of skin
eruptions, edema, minor menstrual irregularities, nausea and constipation, extrapyramidal symptoms, increased and decreased libido-all infrequent and generally controlled with dosage reduction; changes in EEG
patterns (low-voltage fast activity) may appear during and after treatment; blood dyscrasias (including agranulocytosis), jaundice and hepatic dysfunction have been reported occasionally, making periodic blood counts
and liver-function tests advisable during protracted therapy.
Usual Daily Dosage: Individualize for maximum beneficial effects. Oral-Adults: Mild and moderate anxiety and
tension, 5 or 10 mg t.i.d . or q.i.d.; severe states, 20 or 25 mg t.i.d. or q.i.d. Geriatric patients: 5 mg b.i.d. to
q.i.d. (See Precautions.)
Supplied: Librium® (chlordiazepoxide HCI) Capsules, 5 mg, 10 mg and 25 mg-bottles of 50. Libritabs'·'" (chlordiazepoxide) Tablets, 5 mg, 10 mg and 25 mg-bottles of 100. With respect to clinical activity, capsules and
tablets are indistinguishable.
Roche Laboratories • Division of Hoffmann-La Roche Inc• Nutley, N.J. 07110

